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 2 CHAPTER I | INTRODUCTION 
I.1. Anti-Doping in Sport 
I.1.1. Genesis of the fight against doping 
In 1928, the International Amateur Athletics Federation (now the International Association of 
Athletics Federations) became the first International Federation to ban the use of stimulants in 
competition (1). The real starting point for anti-doping programs occurred only later on, when the 
International Olympic Committee (IOC) formed a Medical Commission in 1967, which supervised the 
introduction of anti-doping tests for stimulants the following year during the 1968 Summer Olympic 
Games in Mexico City. The same year saw the adoption of the first Anti-Doping Convention of the 
Council of Europe. 
Two decades later, in 1986, the International Olympic Charter against Doping in Sport was 
inaugurated by the IOC, quickly followed by a revision of the Anti-Doping Convention and its 
acceptance by the Council of Europe in 1989 (1). The fight against doping found a cornerstone in the 
second version of this document as it initiated a crucial dialogue between governments and sport 
authorities for the international harmonization of anti-doping activities. 
With an initial impulse from the IOC and as a response to the doping scandals at the Tour de 
France throughout the 90s and in particular the 1998 Festina affair, the World Anti-Doping Agency 
(WADA) was founded in December 1999 (1). In 2004, the first edition of the World Anti-Doping Code 
(the Code) received international acceptance as the regulation to rule anti-doping world-wide, 
replacing the IOC guidelines previously established (2). The second and latest edition of the Code has 
been released in 2009 (3). Since 2004, the WADA List Committee constituted of a panel of experts 
has been in charge of maintaining and proposing an annual update of the List of Prohibited 
Substances and Methods (the List) (4). In parallel, a Monitoring Program was also launched to 
monitor the use of permitted substances with presumably doping potential through analytical 
monitoring  and to assess the need for regulation of these substances (5). 
Subsequently, National and Regional Anti-Doping Organizations (NADOs and RADOs) were 
created to coordinate the collaboration between International Federations and governmental bodies 
in their joint efforts against doping in sport. Similarly, the World Association of Anti-Doping Scientists 
(WAADS) was established to promote the exchange of scientific knowledge and expertise between 
researchers of WADA Accredited Laboratories as well as for expressing problems and finding 
solutions in a community driven fashion. In 1983, the Court of Arbitration in Sport (CAS) was 
constituted in Lausanne (Switzerland) as the supreme authority in sport to prosecute disputed cases 
and to ensure a complete harmonization of the sanctions among the International Federations at an 
international level (1). 
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I.1.2. Anti-Doping legislation 
A. The World Anti-Doping Code 
The spirit of sport, considered as the essence of Olympism, is the celebration of the human 
spirit, body and mind and its intrinsic values such as ethic, fair play, honesty, respect, dedication and 
commitment, health or excellence in performance. Doping is fundamentally contrary to this ideal and 
is defined as the occurrence of one or more of the eight anti-doping rule violations set in the 2nd 
edition of the Code revised in 2009 (3): 
1. Presence of a prohibited substance or its metabolites or markers in an athlete’s biological 
sample; 
2. Use or attempted use by an athlete of a prohibited substance or method; 
3. Refusing or failing without compelling justification to submit to sample collection after 
notification, or otherwise evading sample collection; 
4. Violation of applicable requirements regarding athlete availability for out-of-competition 
testing, including failure to file required whereabouts information and missed tests; 
5. Tampering or attempted tampering with any part of doping control; 
6. Possession of prohibited substances or methods; 
7. Trafficking or attempted trafficking of any prohibited substance or method; 
8. Administration or attempted administration to any athlete in-competition of any 
prohibited method or substance, or to any athlete out-of-competition of any substance or 
method prohibited out-of-competition, or any type of complicity involving an anti-doping 
rule violation or any attempted anti-doping rule violation. 
Thus, the world anti-doping program, established by the Code, seeks to protect the athletes' 
fundamental right to participate in a doping-free sport and thus promotes health, fairness and 
equality for athletes worldwide, but also to ensure harmonized, coordinated and effective anti-
doping programs at the national and international level with regard to detection, deterrence and 
prevention of doping. Athletes with a sport license have to accept these fundamental rules as a 
condition of participation and are bound by these rules. 
Noteworthy, the 3rd revision of the Code due to come in effect in 2015 will contain additional 
emphasis on the fight against the complicity to doping and an increased length of the two-years ban 
into a four-years ban. 
 
B. The International Standards 
The Code works together with five International Standards harmonizing various technical 
processes related to the practice of anti-doping. These documents are the List of Prohibited 
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Substances and Methods (the List), the International Standard for Testing, the International Standard 
for Laboratories (ISL), the Therapeutic Use Exemptions (TUEs) and the International Standard for the 
Protection of Privacy and Personal Information. 
As a laboratory, the List and the ISL are two documents of outmost importance (4, 6). An annual 
review of the List is conducted by a committee of international experts to update the document with 
additional substances or, conversely, to remove substances (4). The revised document comes in force 
on the 1st of January each year. In order whether to include a substance or method on the List, at 
least two of the following three criteria must be fulfilled (3): 
1. Medical or other scientific evidence, pharmacological effect or experience that the 
substance or method, alone or in combination with other substances or methods, has the 
potential to enhance or enhances sport performance; 
2. Medical or other scientific evidence, pharmacological effect or experience that the use of 
the substance or method represents an actual or potential health risk to the athlete; 
3. WADA's determination that the use of the substance or method violates the spirit of sport 
described in the introduction to the Code. 
The List is divided into 10 classes of substances (anabolic agents, peptide hormones, growth 
factors, stimulants, diuretics, etc.), 3 classes of methods (blood manipulation, gene doping, etc.), and 
2 classes of substances prohibited in specific sports only (alcohol and -blockers) (4). In 2014, close 
to 700 substances appear on the List and may be prohibited either in-competition (IC) or at all times. 
The purpose of the ISL is to ensure the production of valid test results and evidentiary data and 
to achieve uniform and harmonized results and reporting from all laboratories (6). Requirements for 
obtaining and maintaining WADA accreditation are also included, as well as operating standards for 
laboratory performance and a description of the accreditation process. As of March 2014, 32 
laboratories around the world are WADA Accredited, among which the Swiss Laboratory for Doping 
Analyses (LAD) of Lausanne, Switzerland. 
In addition, specific technical recommendations are described in Technical Documents on 
various topics such as the Decision Limits for the Confirmatory Quantification of Threshold 
Substances, the Minimum Required Performance Levels (MRPL) or the Identification Criteria for 
Qualitative Assays. The current ISL is in force since the 1st of January 2012 and is mandatory for all 
signatories of the Code.  
 
I.1.3. Today’s approach and challenges of Anti-Doping 
In order to meet the technological requirements linked to the continuous evolution of the List, 
research in anti-doping is mostly focused on the analysis of products in biological fluids. In 
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consequence, the field piles up with analytical tools and methodologies, rather than offering new 
perspectives and a fundamental look into the phenomenon (original paper in Appendix V.2.1 and 
V.2.2.). Indeed, WADA Accredited Laboratories have to spend most of their resources on developing 
more sensitive and selective methods with the latest and most sophisticated technology. 
Alternatively, the community has paid only peripheral attention to understanding the phenomenon 
as a whole using strong scientific data and alternative sources of information. Technology serves as 
an essential tool to today’s approach which is almost strictly centered on the anti-doping disciplinary 
or judicial process and faces difficulties to break free from it. In practice, the disciplinary or judicial 
process is constituted of two to three successive phases: the problem to identify and to find, the 
collection of evidence for proving the problem and eventually the trial in case of appeal by the 
athlete (Figure 1) (7). 
Search
Detection of a prohibited 
substance/method
Investigation
Evidence gathering,
regulatory breach qualification
Trial
Evidence presentation,
case evaluation
Disciplinary
measure
 
Figure 1. The three phases of the traditional judicial process in anti-doping (7). 
 
The reliability and integrity of the whole process are guaranteed by the very strict quality 
management system offering a complete follow-up and recording of the chain-of-custody from 
sample collection to the reporting of adverse analytical findings, and further on to their presentation 
in court if the athlete appeals against the results of anti-doping tests. However, while this process is 
continuously improving, the efficiency of the fight against doping should be measured according to 
the progresses accomplished towards the fulfillment of detection, reduction, solving and/or 
prevention of doping objectives and not in terms of analytical case numbers. Indeed, these concepts 
stated in the Code also serve important health protection purposes (3). 
Noteworthy, since the 2009 revision of the Code, methods of establishing facts or presumptions 
of facts related to an anti-doping rule violation may be established by any reliable means. This 
addition is a key point as it provides a legal basis for a more flexible fight against doping. Likewise, 
widening the scientific horizon of the field by including an intelligence aspect might be interesting. 
Actually, the situations of doping and traditional criminality share a number of similarities in view of 
their mechanisms and the legal context in which they fit. Forensic Intelligence having brought 
remarkable solutions in recent years to understand criminality and/or in a security perspective, 
exploring this concept is a most promising, though difficult, avenue. The over-riding hypothesis is 
that a proactive Forensic Intelligence program allied to existing substances prohibition and 
laboratory analysis could significantly improve anti-doping efforts. 
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According to the number of abnormal blood profiles, a prevalence of blood doping of 12% has 
been estimated by the International Association of Athletic Federations (IAAF) for the entire 
population of samples collected from elite track and field athletes between 2001 and 2009 (8, 9). 
Interestingly, the prevalence of blood doping in male and female athletes ranged from 3-48% and 1-
46%, respectively, depending on the country of origin. Similarly, a prevalence ranging between 10-
35% has been stated in a survey on doping among German elite athletes in 2008 (10). However, less 
than 2% of the ~260’000 blood and urine samples collected yearly are reported to contain a banned 
substance or to highlight the use of a prohibited method (9, 11). This figure remains quite stable 
despite a tremendous increase of both the volume of anti-doping tests and the sensitivity and 
accuracy of bioanalytical methods. 
Part of the explanation may be found in the perpetual sophistication of doping techniques in 
order to remain undetectable by Accredited Laboratories, the seemingly constant flood of and ease 
of access to new medications with doping properties, the latency between their marketing and 
inclusion to the List and the random nature inherent to out-of-competition (OOC) anti-doping tests. 
Despite the most sophisticated doping methods being the prerogative of elite athletes almost 
exclusively, doping with new and unregulated substances may touch each and every category of 
athletes. 
In recent years, the practice of doping has evolved towards continuous micro-dosing and the 
mixing of a cocktail of designer drugs to achieve the desired performance-enhancing effect (12). 
Contrary to punctually using a single substance in high doses, this methodology offers the advantage 
of resulting in concentration levels that are difficult to detect, being near or below the limit of 
detection (LOD) of the methods. Indeed, as illustrated by the Marion Jones and Lance Armstrong 
cases in 2007 and 2012, respectively, athletes with medical advising on intelligent doping may 
remain undetected throughout their careers despite countless anti-doping tests (13, 14). The 
introduction of OOC anti-doping tests in the early 1990s in response to massive steroid use during 
training periods throughout the 1980s was an enormous paradigm shift in the fight against doping 
(15). Nevertheless, while complementary to IC tests and a major improvement in the deterrence of 
doping ever since, the efficiency of OOC testing is facing organizational, economical and scientific 
challenges. Testing every single athlete on a regular basis would be unrealistic and completely out of 
proportion considering the costs, the volume of samples to analyze and the conflicts with the 
athletes’ privacy it would generate. In this situation, refining the targeting of athletes is a necessity, 
but the increasing complexity of doping makes it difficult to highlight likely cheaters and to test these 
individuals timely before complete wash-out of doping agents. As a result, and with the exception of 
the Athlete Biological Passport (ABP) helping in the targeting of blood doping, OOC tests are still 
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tainted with randomness. Thus, only the tip of the iceberg seems to be perceived with today’s 
approach of the fight against doping. 
Regarding this topic, the use, or attempted use, by an athlete of a prohibited substance or a 
prohibited method is only one of the eight rule violations described in the Code (3). Possession of 
prohibited substances or methods, trafficking or attempted trafficking of any prohibited substance or 
method and administration or attempted administration to any athlete in-competition of any 
prohibited method or prohibited substance also constitute rule violations. Nevertheless, only a small 
research effort has been dedicated to investigating on all these regulatory breaches, leading to 
succinct scientific approaches of limited exploratory nature. In the light of the global scope of the 
Code when considered as a whole, the fight against doping has to multiply the perspectives upon 
which such a complex problematic is addressed. Indeed, considering the growing number of studies 
indicating the existence of doping networks or team-organized doping and a grey/black market for 
prohibited substances, these aspects deserve deeper examination and the elaboration of specific 
strategies (16-19). The Bay Area Laboratory Co-Operative (BALCO) case which occurred in 2003 in 
San Francisco, the Operation Puerto which took place in 2006 in Spain and the Lance Armstrong case 
that came to light in 2012 illustrate these particular concerns. To date, the investigations conducted 
during these prosecutions remain quite unique in their kind, regardless of the magnitude of doping 
that they revealed. 
To some extent, the current situation results from an allocation of human and temporal 
resources having to respond to scientific, legal and organizational needs and challenges. On a daily 
basis, WADA Accredited Laboratories are absorbed by the constant and significant flow of blood and 
urine analyses required by National and Regional Anti-Doping Organizations (NADO and RADO), 
National and International Sports Federations (IFs) and the International Olympic Committee (IOC) 
and the regular demands for case support. Additional concerns, related to research and the 
challenge of developing and validating methods for the analysis of newly prohibited substances and 
methods, as well as proficiency testing programs, internal and external quality management audits, 
ISO 17025 accreditation surveys and the specific requirements of the ISL complete the schedule (6). 
These different aspects naturally constitute a priority for the Accredited Laboratories in the 
accomplishment of the mission entrusted to them. 
David Howman, WADA’s Director General since 2003, declared about it (12):  
 “Testing is – and always has been – the bedrock of the fight against doping in sport; science 
being used against science, with the hope that ‘our’ science – that of the anti-doping community – 
one day becomes too sophisticated for athletes to risk doping.” 
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This statement reveals a perception of anti-doping’s practice where most of the burden of the 
fight has been set firmly on the shoulders of Accredited Laboratories with hopes of solving the 
problem by decisive improvements in screening methods.  
This framework promotes perpetual and endless technological evolution to detect, identify and 
quantify every prohibited substance/method appearing in the List. However, due to the operational 
aspects previously described, researchers and other partners of the fight against doping are bound to 
focus on the disciplinary or judicial process rather than making room for thinking outside of the box. 
As a consequence to this case-by-case and justice-driven approach, anti-doping is still missing a 
strategic vision to understand the phenomenon and to propose long-term solutions. At present the 
resources to gain timely and relevant knowledge to prevent and interrupt doping are limited and the 
field concentrates its efforts on solving isolated cases. 
In parallel, this tunnel vision induces undesirable side-effects on court proceedings themselves 
in case athletes appeal against adverse analytical findings. Depending on the general composition of 
the panel in scientific matters, influence of perceived more than objective science can be significant 
and ultimately influence the overall decision of the panel. Due to this difference of perspective 
between scientists and lawyers, the anti-doping judicial process is often perceived as a discussion on 
the abilities of the scientist rather than the value of the analytical results themselves and leads to 
their erroneous or partial interpretation. Assessment of an anti-doping rule violation has to remain in 
the hands of the judge, as the only entity able to weigh every piece of information in the light of each 
party’s plea. However, where scientists should be presenting analytical results in a balanced fashion 
regarding a potential doping offense to bring scientific support to a case, the judge and lawyers 
request a personal opinion on the significance of an Adverse Analytical Finding (AAF) highlighting the 
presence of a prohibited substance or its metabolites or markers in a biological sample. This common 
practice is problematic and may result in a disputable alteration of the legal process. Indeed, while 
scientists in court are usually clearly identified as parties or as independent scientists, scientists may 
become advocates for one side and may unbalance the legal outcome of a trial as the original 
definition of their roles is sometimes challenged and difficult to respect (20). Due to the blur around 
this aspect of the use of science in the legal system, lawyers seek for procedural irregularities or legal 
flaws as a pretty straight-forward and efficient way to challenge and to rule out the validity of the 
technical expertise of Accredited Laboratories. The testing procedure as a whole is disputed, from 
sample collection, transportation and storage, to chain-of-custody considerations and the very 
bioanalytical process itself from start to finish (21). Since evidence gathering is usually limited to the 
collection of a single AAF, its value is decisive to the outcome of the arbitration. Nevertheless, as it 
comes most often as a single element during court prosecution, trying to find any deviation from the 
rules during the testing procedure has become a regular aim for lawyers to weaken or even 
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invalidate the analytical result (21). As a consequence, the whole process shows insufficient 
emphasis on the physiological meaning of an AAF as the attention of the court is diverted from its 
original purpose, which may bias the whole process. Under the principle of strict liability, the burden 
of proof is for the athletes to defend themselves. Indeed, this rule states that “an athlete is 
responsible, and an anti-doping rule violation occurs, whenever a prohibited substance is found in an 
athlete’s sample. The violation occurs whether or not the athlete intentionally or unintentionally used 
a prohibited substance or was negligent or otherwise at fault.” (3). In view of these circumstances, 
finding legal flaws is a prime and more vulnerable target for the defense which has restricted room 
for action and more often than not very limited scientific expertise. In order to guarantee more fair 
and balanced court proceedings, an important step towards a more comprehensive evaluation of 
AAFs and their relationship to doping could be initiated by collating products of intelligence that 
originate from broader sources of information. 
A further illustration supporting this view may be found in the concept of threshold and non-
threshold substances, where substances are prohibited either above a urinary threshold 
concentration, or so-called cut-off, or regardless of the concentration. If the urinary concentration of 
a xenobiotic is significantly above or below the threshold, the evaluation of a potential doping 
offense is eased, but the closer to the limit, the more complex and the more subject to court 
disputation. Assessing the origin of a non-threshold xenobiotic detected at a very low concentration 
level is equally difficult. Considering the analytical uncertainty and potential bias associated with 
qualitative and quantitative results and potential sources of issues such as sample contamination or 
degradation due to freeze-and-thaw cycles and/or bacterial activity, the qualification of a suspicious 
sample as an AAF by the laboratory and the decision to report it as such may turn into a black-and-
white process. In parallel, as the sensitivity of bioanalytical tools has significantly improved over the 
last decade, with a detection capability in the pg/mL range for more and more substances, assessing 
the origin of low concentration levels and the question of the dose-response effect on performance 
become increasingly difficult (15, 21). A first attempt at addressing this problematic may be found in 
the introduction of MRPL for stimulants, narcotics and -blockers from IC samples in 2009 (22). 
These concentration limits, either defined at the MRPL itself or % of the MRPL, were established as 
safety margins to determine whether a suspicious urinary finding is due to deliberate exposure to a 
doping agent or inadvertent environmental contamination. This concept originates from a case 
where experts faced difficulties in determining if the trace quantity of a prohibited substance 
detected in urine was linked to active consumption several days before the competition or to recent 
exposure in daily life (21). Noteworthy, the lack of performance-enhancing effect in very low 
concentration levels was also pointed out, bringing additional support to the introduction of MRPL. 
Ever since, the technical document has been revised, including floor values at 50% of the MRPL. The 
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idea was to reduce the MRPL while maintaining similar floor levels for reporting non-threshold 
substances prohibited IC only (21). Actually, WADA recognizes individual capabilities for some 
laboratories in their ability to identify a wider range of prohibited substances or lower 
concentrations than other laboratories. Therefore, MRPL have been established as a minimum 
concentration that laboratories must be able to routinely detect and identify to ensure that all 
Accredited Laboratories report results in a uniform way and operate at the same minimal level (22). 
Since these values are neither a threshold, nor a limit of detection, AAFs may result from 
concentrations below the established MRPL. Nevertheless, in practice they may be perceived as 
additional cut-off limits sharing similar concerns as previously mentioned for threshold 
concentrations. 
Therefore, the use and strict compliance to threshold concentrations and MRPL may be 
questionable as this induces a “leap of faith”, which demonstrates pernicious effects on anti-doping 
(23). Accredited Laboratories may be tempted to develop a habit of not reporting AAFs close to the 
threshold limit or under the MRPL to avoid any disputation of their performance in court or simply to 
be facing difficult cases. Actually, this practice is an involuntary outcome of the lack of intelligence 
use, which creates a substantial information gap and complications around the interpretation of 
suspicious findings. A framework of circumstantial information related to the case, the individual 
physiological variability of the athlete under scrutiny and scientific studies addressing the 
consumption of the incriminated substance should be considered more systematically during the 
interpretation of an AAF. Indeed, a tendency may develop to report results within a certain zone of 
comfort rather than within concentration ranges needing a thorough interpretation of the 
physiological meaning or prone to questioning on the analytical work’s reliability. 
 
I.1.4. Recent doping cases 
A controversial incident occurred in 2003 when three times Track Cycling World Junior 
champion Mark French was alleged of prohibited substances use and supply and/or trafficking in the 
months before the Olympic Games in Athens (24, 25). Traces of glucocorticosteroid were discovered 
in used drug syringes, needles, empty vials of equine growth hormone and vials of a homeopathic 
compound found in a rubbish bin in his room at the Australian Institute of Sport cycling training 
facility. While CAS was unable to prove Mark French’s use of growth hormone, he received a two-
year ban from competing and a lifetime ban from the Olympic Games. After the first hearing, Mark 
French appealed the 2004 CAS decision. The panel eventually concluded that there was insufficient 
evidence to confirm beyond reasonable doubt his use and supply and/or trafficking of growth 
hormone, and insufficient amounts of glucocorticosteroid in the homeopathic compound to have a 
significant physiological effect (24, 26). 
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This incident illustrates common issues in the collection and presentation of evidence in court 
that anti-doping authorities are facing when addressing a wider range of rule violations. Indeed, 
despite the seizure of prohibited substances and injection material in Mark French’s room, the 
appeal procedure was successful. This case demonstrates the necessity of a different approach for 
the investigation on doping offenses in the absence of AAFs: forensic science methods may be a good 
answer. 
A more recent example where the handling of injection material followed an appropriate 
methodology for this type of evidence may be found in the 2007 Rowing World Cup case (16) 
(original paper in Appendix V.2.3). During the competition, a plastic bag containing medical 
equipment was discovered in a waste container. Considering the probability that elite rowers may 
have used this equipment, the International Rowing Federation (FISA) assigned LAD with the 
investigation. During the initial phase, the substances were identified as non-doping agents. 
However, the use of an intravenous system is an anti-doping rule violation and syringes, needles and 
used perfusion material were also found alongside these products (3). Therefore, the traces of 
biological material visible inside the infusion tubing were collected for DNA profiling to identify the 
source donors. With the help of contextual information and the information provided by the physical 
examination of the packaging of the seized items, the list of athletes to target could be narrowed 
down to a few individuals, whose DNA profiles were determined after the collection of blood 
samples serving as reference material. A match between the genetic markers of the traces and the 
reference DNA profiles provided evidence on the use of a prohibited method by 8 different rowers 
(16). Accordingly, the FISA hearing panel sentenced the athletes with a two-year ban from competing 
but also the coaches and officials of the National Federation from any future involvement with 
competitive rowing (27). 
The BALCO incident is a more extensive and complex example of the use of police investigation 
methods. Prior to the beginning of the Federal investigation in 2003, an anonymous source provided 
the University of California Los Angeles (UCLA) Olympic Analytical Laboratory with a syringe 
containing a designer anabolic androgenic steroids (AAS) unknown to anti-doping authorities, which 
they named tetrahydrogestrinone (THG) (28). Trevor Graham, a sprint coach whose clients included 
Marion Jones and Tim Montgomery, was later identified as the anonymous informer. When the 
laboratory owned by Victor Conte was raided by the U.S. Internal Revenue Service Criminal 
Investigations Unit and the San Mateo County Narcotics Task Force Records in 2003, large quantities 
of doping agents of all kinds and materials related to the activity of the laboratory were seized (29). 
According to the records, Patrick Arnold, a chemist, was responsible for the design of THG and 
proposed BALCO to distribute it. The investigations revealed that numerous top level athletes were 
listed in the BALCO files, including Marion Jones (three times Olympic gold medalist and twice silver 
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medalist),  Tim Montgomery (100m world sprint record holder), Barry Bonds (baseball homeruns 
record-breaking hitter) and Kelli White (100m and 200m world sprint champion)  (30). This extensive 
investigation resulted in the effective prosecution of several athletes for doping offense in the 
absence of any adverse analytical chemical evidence, which was an unprecedented event in the 
history of anti-doping (29). An interesting outcome of this successful collaboration between the 
United States Anti-Doping Agency (USADA), the Internal Revenue Service Criminal Investigations and 
law enforcement agencies was the recognition of other reliable sources of information for identifying 
and proving a doping case. This legal notice was subsequently included to the 2004 revision of the 
Code (31). Noteworthy, as this scandal raised awareness on the widespread use of doping agents and 
the limitations of the anti-doping legislation in American professional sports, an improvement of 
dope testing programs in the U.S. quickly followed and was directly supported by the White House. 
Similarly, in 2006, the Operation Puerto shed light on the widespread doping network of Dr 
Fuentes, the former Kelme cycling team physician, involving blood doping and transfusion, steroids 
and growth hormones intake, etc. (32, 33) The case arose after the confession of Jesús Manzano on 
systematic doping during the years he spent cycling under the medical supervision of Dr Fuentes. As 
doping is an offense under the Spanish penal law, the Guardia Civil conducted an investigation and 
seized 200 blood bags and 105 drugs and doping agents (testosterone, human recombinant 
erythropoietin, growth hormones, insulin,…) at the office and home of Dr Fuentes. Furthermore, a 
training and doping calendar containing a coded list of approximately 100 names was discovered, 
which included a majority of top level cyclists and pointed out serious suspicions of blood doping on 
a number of professional tennis and football players. By overlapping this information with the 
hematological follow-up of professional cyclists, a few athletes who had previously won the most 
prestigious races in cycling (Tour de France, Vuelta, Giro, Pro Tour, Olympic Games, etc.) could be 
identified and convicted of doping. While the collaboration between sport authorities and the 
Spanish Police in leading the investigation was successful and promising, their joint efforts faced 
reluctance from the political world to shed light on the rest of the athletes appearing on the list. 
In 2012, the USADA vs. Lance Armstrong case further illustrated the invaluable role of criminal 
investigations in detecting highly professionalized organized doping. Despite the lack of direct 
bioanalytical evidence, the USADA’s investigation was successful in collecting sworn testimony from 
26 people, including 15 riders with knowledge of the US Postal Service Pro Cycling Team doping 
activities, as well as 11 teammates of Lance Armstrong. In particular, 9 of his teammates were also 
clients of the Dr Michel Ferrari who supervised the doping program among the cycling team. The 
evidence collected during this case covers the entire career of Lance Armstrong since 1998 and are of 
documentary, scientific, direct and/or circumstantial nature. Indeed, the investigation allowed 
gathering a multitude of banking and accounting records reflecting more than one million dollar in 
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payments to Dr Ferrari and extensive email communications during a time period in which Lance 
Armstrong claimed to not have a professional relationship with his doctor (13, 34). Furthermore, a 
vast amount of additional data have been collected, including laboratory blood test results 
throughout his career and the scientific expertise realized afterwards to interpret these data from a 
longitudinal perspective. These elements as a whole allowed demonstrating in a univocal way the 
use, possession and distribution of performance enhancing drugs by Lance Armstrong. According to 
the USADA, “the US Postal Service Pro Cycling Team ran the most sophisticated, professionalized and 
successful doping program that sport has ever seen.” (34). Under this program, Lance Armstrong 
would not only win the Tour de France seven consecutive times between 1999 and 2005 to set an 
unprecedented record in cycling’s history but would also not be tested positive.  
 
I.2. Rationale and hypotheses on areas for improvement 
These examples illustrate a tactical use of information to provide investigative leads and to feed 
the judicial process. However, these cases would hardly have come into scrutiny without confessions 
or denunciations and show the lack of a rationale and model for gathering relevant information and 
detecting doping issues. Therefore, a more systematic and in depth use of data appears necessary to 
favor a proactive detection and identification of suspicious activities. In order to truly deter athletes, 
the timely dimension is of outmost importance. Indeed, the impression that only the unlucky or most 
obvious ones get caught may naturally survive as long as a rule violation is discovered only years 
after the athlete having enjoyed all the fame and glory of past victories. 
As a result, fight against doping needs to consider other scientific avenues to understand and 
highlight doping offenses so as to exert efficient preventive or disruptive effects and to support 
educative or policing decisions by regulatory bodies. The opportunity to gather broader, yet equally 
relevant, sources of information should be taken in order to understand doping and its countless 
variations and to support cases or situations that need action whether in reducing a risk, preventing 
some substance use, legitimating observed results or leading to punishment by courts. Anti-doping 
needs scientific innovation rather than technology innovation. Indeed, performance of complex 
analytical chemistry and biochemistry tools and WADA accreditation of laboratories have been the 
center of attention whereas gathering and exploiting information coming from a multitude of 
sources has remained obscured by technological and quality management debates. 
In this view, this thesis proposes to discuss the problem of doping and to assess the additional 
value of Forensic Intelligence for implementing more specific and efficient models to prevent, reduce 
and/or solve doping in sport. The potential of an Anti-Doping Intelligence to address the different 
aspects of the problem will be discussed relying on a logical reasoning model similar to the one used 
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to understand and impact on criminality. The phenomenon of nicotine consumption in sport through 
smokeless tobacco use, and more specifically snus, will serve to evaluate the extent to which 
processing information coming from a variety of sources may be inserted into this model. 
On a side note, doping concerns the sports community as a whole and may be perceived as a 
public health issue. Elite and professional athletes represent only a small portion of all the sports 
enthusiasts worldwide. Doping among amateurs and practitioners of sports not legally bound by 
WADA-IOC is an equally important matter. Since this extensive part of the community is usually not 
subject to anti-doping controls, measuring the prevalence of doping through analytical monitoring is 
difficult, if not impossible, and requires questionnaires, such as randomized-response surveys. 
Sanctioning these sports enthusiasts is very unlikely and might be difficult to justify in most 
instances. Likewise, it would probably go beyond the primary scope of WADA for legal, organizational 
and economical reasons. Intervening on doping in this population requires the development of 
preventive and educational tools rather than using the threat of a sports ban to exert a deterrent 
effect. While the issue of doping is important regardless of the type of athlete and sport, the thesis 
will focus on elite athletes bound to WADA-IOC regulation. 
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II.1. Forensic Intelligence 
II.1.1. General concept 
Forensic science is an important aspect of the criminal justice system, where it serves to lead 
investigation or to support law oriented questions with scientific information. Analysis can be based 
on logic besides tools. 
Forensic Intelligence embraces this approach and pursues a further goal in the study of criminal 
activities by bringing a broader logical dimension to the interpretation of trace data detected and 
collected after a litigious activity. The characteristics of these remnants are extracted and described 
before being integrated to a structured memory containing information previously acquired on the 
phenomenon. Afterwards, inference structures are built upon logical analysis of these data, allowing 
revealing a network of hypothesized links between fresh information and material already 
memorized. This gathering of knowledge on the criminal phenomenon under scrutiny can support 
decision-making of tactical, operational or strategic nature in the area of law enforcement for crime 
solving, reduction and/or prevention. 
In practice, Forensic Intelligence endorses three levels of function, namely tactical intelligence, 
operational intelligence and strategic Intelligence (Figure 2). 
 
Figure 2. Organization and aims of each level of Forensic Intelligence. From the reactive micro-level of tactical 
intelligence to the crime reduction planning meso-level of operational intelligence and the future-oriented and 
proactive global-level of strategic intelligence. 
 
These different levels of intelligence operate on an increasing spatial and temporal dimension. 
However, sharing a logical reasoning on the trace and numerous sources of information, these 
concepts interact rather than being completely distinct processes. Therefore, the delimitation 
between these different levels should be perceived as flexible due to a natural overlap. 
An interesting feature is the ability of Forensic Intelligence to propose a proactive and global 
response for the prevention and solving of criminal activities rather than focusing on solving a single 
past event (35). 
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II.1.2. Levels of Intelligence 
A. Tactical intelligence 
Tactical intelligence is a reactive approach supporting real-time decision-making of front-line 
law enforcement officers and proposing leads to investigations at a case level. The logical analysis of 
traces provides accurate, timely and usable information for crime detection, for identification, 
localization and arrest of potential offenders, and for gathering of evidence for prosecution in court 
(36) (Figure 3). 
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Figure 3. Structure of Forensic Intelligence through logical processing of information supporting tactical 
intelligence  to feed  the criminal judicial process, operational intelligence to plan crime reduction actions and 
strategic intelligence to develop future-oriented and long-term solutions (37).  
 
Tactical intelligence alone does not seek to bring to light criminal activities that exist either at a 
scale larger than the individual offender or that constitute repetitive issues (38). The detection of 
such criminal problems and their subsequent solution, reduction or prevention require broader 
sources of information and more thorough exploitation of traces as compared to the short-term 
case-by-case approach of tactical intelligence. 
 
B. Operational intelligence 
Operational intelligence calls for a larger organization level to provide a comprehensive 
understanding of criminal trends, to ensure a follow up and to help in the coordination of actions 
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(Figure 3) (38). This concept seeks to impact on repetitive problems such as serial crimes, the activity 
of criminal organizations or illicit drugs trafficking by promoting a more proactive and mid-term 
oriented approach of problem-solving. Indeed, operational intelligence assists decision makers in the 
targeting and deployment of law enforcement resources as well as in the planning of actions for 
crime reduction or prevention (39). 
With the help of exploratory, statistical and visualization methods related to crime analysis, 
extensive amounts of information saved in a structured memory are logically processed to detect 
geographical and/or temporal problems, to determine the type of offenders and to identify criminal 
patterns, or so-called modus operandi. As this analysis process is iterative due to the constant flow of 
new information filling the memory, operational intelligence supports intelligence-led policing with 
continuously refined and updated knowledge. 
 
C. Strategic intelligence 
Strategic intelligence operates at a third and more global level of organization. Criminality is a 
complex phenomenon constantly evolving over space and time due to changes in demographics, 
economics, politics, environment, etc. Therefore, strategic intelligence encompasses these 
parameters in a criminological perspective as well as sub-levels of Forensic Intelligence. The 
reasoning here is a multivariate approach aiming for the description and understanding of the 
mechanisms behind criminality as part of an environment in perpetual change (Figure 3) (38). 
Strategic intelligence is future-oriented and resolutely proactive as it intends to foresee the 
development of potential or emerging criminal threats by identifying and resolving system 
vulnerabilities proactively. An interesting feature is the ability to identify areas where policing and 
harm minimization actions may achieve positive results (35).  
This approach seeks to impact on the phenomenon as a whole rather than on specific criminal 
activities. Strategic intelligence can help designing most efficient strategies to restrain identified 
problems. This concept is conducive to proposing long-term problem-solving policies as well as 
preventive and educative actions or programs. Due to the nature of the goals pursued, strategic 
intelligence might also take a political dimension. 
 
II.1.3. Structured memory 
Forensic Intelligence is embracing a number of scientific disciplines to detect, collect, describe 
and compare traces related to litigious activities, which once collated with other sources of 
information and exploited using crime analysis tools provide a better understanding of criminal 
patterns. Considering criminality as a global phenomenon rather than isolated cases, the reasoning 
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does not limit to the study of physical, biological or chemical evidences to answer source and activity 
questions and to support decision-making at tactical, operational and strategic levels. 
Actually, the operation of Forensic Intelligence depends on a structured memory of traces and 
information to gather knowledge and produce intelligence on a criminal phenomenon. As an 
organized repertoire of systematically and continuously updated or possibly applied inferences 
reasoning, the memory represents the knowledge we have at a certain time about the criminality 
under consideration: current criminal problems or patterns, serial crimes, cases linked, etc. (Figure 
4). 
Problem
Phenomenon
Acquisition
Intelligence /
Decision-making
Memory
new information
follow up
impact
Integration Analysis
 
Figure 4. Logical processing of new information acquired and integrated to a structured memory containing 
previously stored information (40). The analysis is an iterative and cyclic process that allows transforming these 
raw data into timely and usable information to support decision-making in order to impact on the criminal 
phenomenon under scrutiny. 
 
In practice, information on a criminal phenomenon is first acquired and then integrated into a 
follow up framework. Characteristics of these new data are extracted and sorted out prior to being 
merged with previously memorized information, allowing drawing inference structures that reveal a 
network of hypothesized links. This reasoning process is entirely based on postulating and testing 
assumptions on the relation between items organized in the structured memory. 
The analysis of the memory is an interpretative step where each new piece of information may 
confirm the predicted truth-value of hypothesized links and/or result in the connection of sets of 
information originally considered as distinct. Conversely, the outcome of this logical process may 
question or even exclude the existence of links previously assumed. Depending on the perspective, 
new pieces of information may serve for immediate use or may be stored to feed future inference 
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processes. These new items may be organized in a short-term memory for direct exploitation on a 
specific criminal case, or may be integrated to a long-term memory to depict criminal trends or series 
or to identify system vulnerabilities. 
Therefore, the follow up process is iterative and dynamic as organizing and scrutinizing the 
memory in order to infer new information is most likely going to modify the picture of a 
phenomenon and to result in an update of the memory (Figure 5).  
Retrieve
Modify
Update the memory
Set of cases
Scrutinize
Memory
Analysis
 
Figure 5. The logical analysis cycle of the information stored in the structured memory (41). 
 
The coherence of the memory is ensured by this logical methodology. An interesting outcome is 
the ability to synthesize a set of information describing the phenomenon under scrutiny. This 
reasoning process provides decision makers with a real-time insight into criminality and accurate and 
usable information to conduct investigations, to help in the coordination of law enforcement actions 
and in the designing of policing operations. In case the problem has not been completely solved by 
these actions, but also due to environmental variations or the attractiveness of alternative targets, 
isolated authors as well as criminal organizations may have to adapt their modus operandi in order to 
survive and to pursue their activities. This shift in criminality requires the acquisition of new 
information to feed and refresh the Forensic Intelligence process in order to ensure up-to-date and 
exploitable knowledge. Therefore, the reasoning works in a cyclic fashion. 
On a practical note, while finding links may appear somewhat straight-forward, linkage 
blindness may occur due to the increasing complexity of the memory, the incompleteness of the data 
and constraints of political, legal or organizational nature (41). Indeed, as the structure of the 
memory becomes more sophisticated with its expansion, the network of links may become a blur 
and links between objects, individuals and/or events may be missed. As a way of reducing the 
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splitting of information, the memory as a whole or as sets of smaller size may be visualized using 
relational diagrams or maps (Figure 6). 
Suspect ASuspect B
Suspect C
Drugs traffickingTrafficking of stolen vehicles
 
Figure 6. Simplified example of a relational diagram to visualize the links between objects, individuals and/or 
events related to criminal activities such as drugs and/or stolen vehicles trafficking. 
 
Noteworthy, the concept of intelligence is a particularly versatile approach, as illustrated by its 
applications in the economical, sociological or demographical fields. 
 
II.2. Perspectives for Anti-Doping 
II.2.1. Transposition of the concept 
The concept of Forensic Intelligence previously described may be transposed into Anti-Doping 
Intelligence by relying on a similar methodology and shifting the paradigm to the problem of doping 
in sport (Figure 7). 
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Figure 7. Transposition of the Forensic Intelligence concept into Anti-Doping Intelligence. 
 
At tactical level, where Forensic Intelligence is focusing on the individual offenders, Anti-Doping 
Intelligence would be focusing its attention directly on the athletes. The exploitation of traces, 
including bioanalytical results, documents linked to the practice of doping and the distribution, 
administration and/or consumption of doping agents, seizures of prohibited substances, etc. would 
follow the perspective of proposing investigative leads on athletes and/or individuals responsible for 
the diffusion of doping as well as bringing scientific evidence to legitimate punishment from anti-
doping authorities or to support the anti-doping judicial process in case of appeal. 
Likewise, at operational level, the attention on serial crimes and criminal organizations would 
switch to tendencies in the abuse of prohibited substances, organized doping and the trafficking of 
doping agents. Seriality might be defined as the recurring character of these doping activities or 
linked to doping. The use of hormones and/or peptides represents a form of systematic doping as 
the methodology involves continuous intake over a long period of time rather than a single intake 
during a competition. Blood doping with human recombinant erythropoietin (rEPO), whose abuse 
began in the 1990s and shows successive waves of use each time a new generation of the 
therapeutic medication enters the market, also illustrates a form of seriality. Likewise, the continuity 
and extent of AAS abuse since the 1980s as well as their trafficking set on the worldwide scale are 
repetitive problems. As an example, state doping in Eastern Europe was organized systematically by 
governments in a quest for international recognition as opposed to their somewhat lower economic 
and scientific performances (1). Although this practice was characteristic of all the satellite countries 
of the Soviet Union, the German Democratic Republic (East Germany) also used this strategy to be 
recognized as a state in its own right after the division of Germany at the end of the Second World 
War. This relatively small country achieved incredible sport results at top level, which were 
acclaimed worldwide, creating a strong image despite a negative political and economical situation. 
AAS and other synthetic products developed in secret research laboratories to practice systematic 
doping are largely responsible for these extraordinary sports performances and for having helped to 
maintain the myth over decades. The actual situation of sports physicians supervising organized 
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doping programs, from import, even sometimes production, to administration of products and 
monitoring of the athletes’ physiological values to remain undetectable is a similar issue. The 
exploitation of traces would serve to detect these problems, to assess their temporal and 
geographical dimensions and to identify the modus operandi. Expanding the knowledge on doping or 
related activities should result in a better understanding of the structure of the phenomenon and its 
mechanism of operation. Regarding this topic, script analysis is an innovative way to study complex 
forms of crime and to design more efficient strategies of action (42). This concept considers the 
commission of an illegal activity or any rule violation as a modus operandi rather than as a single 
event. Therefore, scripts analysis intends to map the complete sequence of actions and decisions 
before, during and after a rule violation to identify its key stages and to propose a fuller range of 
possible intervention points. By revealing potential weak spots where the commission process might 
be disturbed, disrupted or even prevented, this methodology seeks to reduce the opportunities and 
resources and increasing the risks associated with the rule violation  (42). As scripts analysis can be 
retrospective, studying the organized doping cases mentioned previously would be invaluable in 
order to identify and counter the mechanisms underlying this particular form of rule violation. 
Eventually, at strategic level, the emphasis would be put on understanding the doping 
phenomenon as a whole instead of criminality. The reasoning would seek to determine the 
predisposing factors of doping initiation among the sports community, whether they might be 
human, environmental, economical, or even political.  With an extensive comprehension of doping 
mechanisms, the strategic dimension of intelligence might allow preventing the phenomenon by 
proposing solutions aiming at minimizing, if not neutralizing, the influence of the predisposing 
factors. 
Considering the significant gap between the estimated prevalence of doping in elite sports and 
the annual WADA statistics on AAFs, the opportunity to provide a more in-depth exploitation of 
information at disposal or carried by traces should be seized. A series of perspectives for Anti-Doping 
Intelligence will be discussed in the following paragraphs to illustrate these concepts. 
  
II.2.2. Organized doping and trafficking of doping agents 
A. Overview 
With the 2013 WADA Prohibited List being estimated to cover approximately 700 substances, 
trafficking of doping agents is an attractive and lucrative business of probably underestimated 
dimension that may follow complex pathways and involve criminal organizations (4, 5, 17). 
Supply sources may vary quite notably depending on the type and legal status of a substance. 
Indeed, pharmaceutical preparations containing doping agents such as pseudoephedrine can be 
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readily available over the counter and require no prescription. In contrast, pharmaceutical products 
for therapeutic use, like rEPO or human growth hormone (HGH), require a prescription or may also 
be counterfeited by clandestine laboratories or diverted from production stocks of the 
pharmaceutical industry and supplied on the grey-market (unofficial and usually unauthorized by the 
original manufacturer) (29). Therefore, both original and counterfeit doping agents are being 
trafficked. In any case, a number of illicit products sold on the black-market (underground illegal 
market) by drug dealers, such as cocaine or amphetamines, are also doping agents. 
In consequence, doping turns out to be a complex phenomenon considering the vast variety of 
substances, supplied through both legal and illegal trading routes, and the extensive connections 
between the people involved in these distribution networks. While doping may appear as the doing 
of an athlete on its own, it always involves one or several entities in the supply of doping agents or in 
their use, whether the friends and relatives of the athlete, or the medical staff, manager and 
teammates of a sport’s team, or chemists, biologists and pharmacists, or pharmaceutical industries 
and clandestine laboratories, or criminal organizations, drug smugglers and dealers (Figure 8). 
 
Figure 8. Doping network and the diversity of potential links between its different entities. 
 
Since there is no regulation on the production and trafficking of doping agents in most parts of 
the world, there are very fertile grounds for the development of clandestine pharmaceutical plants. 
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On the whole, industries in Thailand, China, India and Russia play a major role with numerous 
production sites and well-established trading routes (17). Actually, statistics on seizures of doping 
substances indicate industries in China and India as the fastest growing source of suppliers of the 
international grey-market. The numbers reported are also corroborated by their ever-expanding 
pharmaceutical industries. On a global scale, producers in Thailand, China, India, Russia, Greece and 
Mexico account for approximately 55% of the distribution of doping agents. Besides, a hint on the 
involvement of the industry in this business may be found in the overproduction of rEPO, which is 
estimated at about five to six times the real worldwide treatment requirements. Indeed, a panel of 
experts supported by governmental institutions pointed out a significant imbalance between the 
production of pharmaceuticals with doping properties, namely rEPO, HGH and testosterone, and the 
therapeutic requirements of patients (17). 
According to the statistics, the production of AAS might be estimated to reach approximately 
700 tons a year, which is enough to supply 15 million people annually. In particular, approximately 70 
tons of testosterone are produced to meet the requirements of 1.5 million people each year. 
Similarly, rEPO and HGH production reach approximately 34 million phials a year, enough to supply 
up to 2 million people (17). The diffusion of doping, which accounts for approximately 15.5 million 
people, does not concern only top-level athletes, but also various categories of individuals. As 
mentioned in the Donati report on World Traffic in Doping Substances, doping as a whole is 
constituted of approximately 35-37% athletes of all levels, 38-40% body-builders and gym-goers, 
which include private surveillance agents, 4-6% military and police forces, 1-2% people involved in 
show business and 15-20% false treatments (17). According to a recent survey conducted in the 
Netherlands, approximately 8.2% of fitness centre members use performance enhancing drugs (43). 
The Internet has brought new horizons to the trafficking of doping substances in simplifying and 
securing its global development. The lack of regulation on the production of doping agents in most 
countries of the world and the multiplication of online “pharmacies” ensure the ease and safety of 
this grey-market, which translates into a steady growth. Indeed, there is significantly less risks for the 
producers and traffickers to leave the stocks in the country of origin and to send them by postal 
service in small quantities than to load a truck with large quantities and undertake a journey in the 
open through several customs to reach the final destination. 
Several different forms of trafficking have been identified (17). The traditional movement of 
doping agents consists in loading large quantities onto a conveyance for transportation to 
intermediate locations, where a part of the shipment is delivered, while the rest continues to the 
next destinations. This form used to be the most popular previous to the e-commerce era and is 
becoming less frequent nowadays. A more common form, which is similar to the traditional one, 
relies on the postal service system for final dispatch after transportation to the intermediate 
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location. The advantage is to allow the gathering of different doping substances in a specific place to 
build up online “pharmacies” which will send small packages to the purchasers. Eventually, the most 
straightforward and fastest growing form involves stocking doping agents directly on-site or in the 
production country prior to their shipment to the online purchasers. 
Although the supply of doping substances may seem to be set on the individual scale of the 
athlete, its major dangers and risks lie in organized doping and in the market largely linked to and 
dominated by international criminal organizations. The Italo-American Mafia has been in control of 
the trafficking of AAS and HGH in the United States up until the mid 90s and the onset of the so-
called Russian Organized Crime (ROC) as a predominant actor on the grey-market (17). Soon 
afterwards, Asia’s share into the production and worldwide trafficking of doping substances 
considerably expanded to replace the Russian Mafia as the leading power of the grey-market. 
Noteworthy, in several instances the trafficking of illicit drugs and doping agents as well as 
counterfeit medicines has been found to originate potentially from the same criminal organizations 
(44). 
On a side note, the Fédération Internationale de Football Association (FIFA) and the Union of 
European Football Associations (UEFA) have pointed out during the Anti-Doping in Sports Consensus 
Meeting held at Home of FIFA in Zurich on November 29th 2013, that match-fixing and doping are 
linked to the same criminal organizations in many instances. Indeed, they have found an intelligence 
link between illegal betting and doping. 
 
B. Intelligence and legal context 
As defined by the Code, the anti-doping system is an administrative process and aims at 
prosecuting athletes violating an anti-doping rule. Nevertheless, the angle at which doping is 
addressed throughout the world may reflect differences between legal systems. Indeed, while 
administrative processes are the general norm and the underlying philosophy of the Code, doping in 
sport is a matter of public criminal law in Spain, Italy and Belgium, defining a legal framework for 
actions of criminal justice nature and for the use of police investigations (25). Alternatively, countries 
such as the United States and Australia define doping in sport as a matter of private law. Therefore, 
inquiries into rule violations are carried out between the IF and the athlete, prior to being 
transmitted to the National Anti-Doping Organization serving as an administrative body, or to a 
private arbitration panel, most likely the CAS. In contrast, the situation in France since the revision of 
its Anti-Doping Act in 2006 is a compromise between a reinforced administrative process and the 
criminalization of specific activities supporting the doping of athletes (45).  
Pursuant to the administrative nature of the Code, and despite the awareness of the anti-doping 
community on the need for developing intelligent tools to link the different entities of a doping 
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network, the fight against doping concentrates on testing. In contrast, the use of criminal justice 
mechanisms in the countries mentioned previously legitimates a wider range of investigations on 
organized doping and taking action against people involved in doping networks. Indeed, these very 
specific countries consider doping as a criminal offense, which allows involving law-enforcement 
agencies in the anti-doping system. 
Except in these jurisdictions, doping networks enjoy and live through the relative safety created 
by the lack of collaboration, and legal ground in the first place, which persists in sharing relevant 
information held at different levels by the WADA, National and Regional Anti-Doping Organizations 
(NADO and RADO), National and International Sports Federations, the IOC, WADA Accredited 
Laboratories, national customs and border agencies, the World Customs Organization (WCO), 
national police services, the European Police Office (EUROPOL) and the International Criminal Police 
Organization (INTERPOL). Indeed, these entities are as many sources of information coming from 
their direct contact with athletes, sports teams or sports physicians, from prevalence studies 
conducted by the Laboratories, customs seizures of doping agents or even police investigations 
where doping might be part of a criminal activity. After collection and structuring of the information, 
its logical processing under the principles defined in the concept of Forensic Intelligence may prove 
useful and particularly efficient for identifying systematic doping or trafficking networks and to 
neutralize, disrupt and/or prevent these activities (36). While relevant information is in possession of 
anti-doping authorities and their partners, implementing Anti-Doping Intelligence is facing a major 
obstacle in the general lack of legal regulation for exchanging data. As a key piece to the backbone of 
an intelligent approach, a legal framework should be settled and may be found in establishing 
national and international conventions to legitimate the collection and sharing of information related 
to doping. 
With few exceptions partners of the fight against doping are non-governmental bodies, a 
situation which limits their freedom of action in addressing the phenomenon from a more global 
perspective. Ultimately, governments can decide whether to include or not the possession and/or 
trafficking of prohibited substances to national criminal codes, regardless of WADA’s opinion. As the 
Code defines doping as a violation to the rules defined in this administrative regulation, treating 
doping as a criminal act is arguable. Nevertheless, athletes of all levels represent approximately a 
third of the population using doping agents prohibited by WADA, in particular AAS (17). Considering 
that top-level athletes are a minority bound to the Code’s regulation and in most instances the only 
group of people under continuous medical supervision, it is obvious that the general population of 
users may be at high health risks. Indeed, they tend to show little knowledge or care about the 
products’ chemistry and the prescribed daily dose and underestimate the side-effects of regular use. 
Since these people do not fall under the legislation of anti-doping, the trafficking organized around 
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this huge part of the market is also considerably facilitated. In these views, the argument of the 
countries previously mentioned to treat doping in a similar way to illicit drugs use and trafficking is 
comprehensible. One way or another, raising awareness on doping as a public health issue would 
help to legitimate the establishment of the legal grounds necessary to implement the different 
aspects of Anti-Doping Intelligence. 
 
A Forensic Intelligence approach has been developed at the School of Criminal Justice (ESC - 
Ecole des Sciences Criminelles) in Lausanne, Switzerland, to help understand and fight illicit drugs 
trafficking as well as in the detection and description of criminal organizations involved in the 
counterfeiting of pharmaceuticals. Doping agents covering a large part of these categories of 
substances, the methodology can be described and directly transposed to anti-doping. Therefore, the 
term ”product“ will be used for illicit drugs, counterfeit medications and doping agents 
indistinguishably. 
While online sales show a growing popularity, the concept of strategic internet monitoring 
might bring interesting information. Indeed, the use of search engines and automatic alert systems 
on specific keywords allows listing and following the online sales websites in order to obtain a large 
panorama of the market and to detect the emergence of new trends (46). The extraction of digital 
data on the website coding, the geographical location of the host, the contact address, etc. might 
indicate the origin of the products and sales areas across the world, the geolocation of the retailer 
and sometimes its identity. The analysis of these digital data might also highlight a link between 
online sales websites and, therefore, refine the comprehension of the structure and activity of the 
market. Applying this methodology to the analysis of forums, blogs, social networks and other online 
media might significantly contribute to increasing the knowledge on the activities of the distribution 
networks. These tools provide an overview of supply and demand and allow estimating the 
consumption prevalence of the substances and to follow its evolution. Physical and chemical profiling 
of seized products brings complementary information in order to infer the source of production. 
The product itself is a trace resulting from the trafficking network and constitutes, therefore, a 
direct and major element for understanding the criminal organization. It carries information 
providing indications on source and activity decisive in the perspective of decoding the structure of 
the phenomenon. Drug profiling is this process of extracting the physical and chemical profiles to 
identify links in order to apprehend the organization of illicit drugs trafficking activities (35, 46). The 
optical examination of the physical characteristics of the packaging and product focuses on a 
multitude of parameters, including the name, logo, formulation (vial, pill, gel cap, cream, etc.), color, 
dimensions, batch and/or serial numbers, country of production, language and destination. These 
elements provide important information linked to the producer and its modus operandi. Following 
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the physical examination, active compound and excipients of the seized product are identified and 
measured by chemical profiling, allowing highlighting a link between similar products or, 
alternatively, between different products from the same production line (47, 48). 
Physical examination, chemical characterization, digital data and other circumstantial data are 
stored in a structured memory for further exploitation. Then, inference models are built upon these 
data to link product seizures, highlight distribution networks and identify sources of supply. These 
models allow evaluating the grey and black market in order to support decision-making and 
prioritizing (49). Also, chemical profiling might be able to identify a potential health risk as the 
composition and concentration of the active compound in counterfeit medications often differs from 
the indications on the packaging (44). 
Considering an operational intelligence perspective, similar chemical and/or physical profiles can 
bring to light a link between separate product seizures or trafficking cases that appeared unrelated a 
priori (35). Strategic intelligence can serve to visualize the organization of trafficking networks, from 
production to distribution, in order to identify key points and tendencies in the supply and use of 
illicit products. Establishing maps of the geographical zones responsible for the production of these 
compounds and of the consumption prevalence of specific forms of doping across the world is also 
possible. 
The extraction of the physical and chemical profiles of doping agents seized by the customs and 
the strategic internet monitoring offer a global view of the market, allow identifying new 
medications with a doping potential, and measuring the extent and seriousness of a doping 
epiphenomenon. Drawing schemes indicating relations between individuals and/or substances could 
greatly improve the understanding of the structure of the trafficking and, therefore, the success rate 
of interventions aiming at tackling these activities. Actually, relational diagrams are a common 
visualization method to help in the process of describing the links that constitute the backbone of 
the phenomenon. Collection and sharing of sensitive information are essential to have a real time 
evaluation of the size, evolution or mechanism of a doping phenomenon. Nevertheless, custom 
seizures represent only a small percentage of the market for prohibited substances as the numbers 
of the parcels controlled when going through the customs is limited and as a seizure can be made 
only for products with a specific import and/or use regulation. Therefore, strategic monitoring and 
profiling are complementary tools. 
Exploring this approach would be even more interesting in anti-doping as it may help refining 
the targeting of athletes or sports teams, identifying doping promoters and deploying adequate 
operations to dismantle core ramifications of doping networks. The overall advantage of this 
approach would be to elicit information of a different and improved nature compared the one 
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currently exploited, which may prove efficient in supporting not only tactical measures, but also 
operational or strategic operations. 
From a practical point of view, implementing and regulating Anti-Doping Intelligence might be a 
difficult task due to several challenges and limitations. Since the boundaries and function of anti-
doping are particular to each and every country, the harmonization of this approach might face legal 
obstacles. While some countries might require only little legislative amendment to implement Anti-
Doping Intelligence, other countries might need substantive legal reform. Indeed, different parts of 
the world consider doping either as a matter of administrative law or as belonging to criminal law, 
with all possible degrees of variation in between. Therefore, the establishment of an intelligent 
system is dependent upon the will of governments, and on anti-doping authorities to press on them, 
to legislate over this question. In addition, centralization is essential to reduce the fragmentation of 
information. Indeed, despite the existence of databases such as WADA’s Anti-Doping Administration 
and Management System (ADAMS), other at individual NADOs and even the ABP and the urinary 
steroidal passport at Accredited Laboratories, as well as investigation information, an organized 
Forensic Intelligence system is lacking. Since knowledge on doping activities is dispatched between 
all the stakeholders, a principal location to gather information and to operate intelligence processes, 
perhaps at WADA, would be necessary. This structure would help to communicate relevant and 
timely information with anti-doping professionals and to support coordinated actions. Again, this 
raises legal, organizational and economical challenges. 
 
II.2.3. Highlighting doping with comprehensive and indirect approaches 
As illustrated with the 2011 WADA/UCI v. Alberto Contador Velasco & RFEC case,  the source of 
low-levels of doping agents, in this case clenbuterol, is difficult to ascertain due to the probability of 
environmental or food contamination or any other potential explanatory reason (50, 51). Indeed, 
due to clenbuterol’s disposition in animals’ edible tissues, consumption of meat contaminated with 
this illicit growth promoter may result in considerable issues with regards to doping controls (52). In 
2010, within two days after returning from a competition in China, urine samples from a team of 
athletes were collected as part of regular doping controls and every specimen was reported to 
contain low amounts of clenbuterol  (53). This situation immediately triggered the initiation of a 
study where urine samples were collected from 28 volunteers after returning from a trip to China. 
The sympathomimetic amine was detected in ~79% of the samples, indicating a widespread food 
contamination issue despite official prohibition of clenbuterol for animal husbandry. Likewise, FIFA 
initiated investigations on potential food contamination in Mexico, the host country of the FIFA U-17 
World Cup 2011, after facing several clenbuterol AAFs among the Mexican national team (52). Meat 
samples were collected in team hotels during the tournament in addition to the regular doping 
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controls. Subsequent analysis highlighted a clenbuterol prevalence of ~52% in urine specimens and 
~30% in meat samples. 
Since similar situations tend to happen more frequently, especially due to the steady increase in 
sensitivity of analytical instruments, a multiparameter approach in anti-doping might become 
essential for interpreting bioanalytical results. The current situation illustrates the need for 
collaborative research between experts in the fields of analytical chemistry, endocrinology, genetics, 
pharmacology, physiology and sports medicine to understand and address each specific doping 
phenomenon and case within a forensic science framework (31). Collating analytical results, also 
including atypical findings and, if any, previous AAFs, and longitudinal monitoring of biomarkers with 
individual physiological particularities of the athlete, epidemiological, sociological, circumstantial, 
etc. information and products of Anti-Doping Intelligence into the structured memory may provide a 
logical framework enabling fit-for-purpose decision-making. 
From an intelligence perspective, the structured memory attached to every athlete would help 
refining the targeting of suspicious athletes and identifying the likely cheaters. In addition, the 
memory would also serve to strengthen the use of other parameters than pure analytical chemistry 
results to detect and assess a potential rule violation and to support cases brought to court on 
appeal. Actually, when considered with other pieces of information, a xenobiotic detected at a 
concentration below the threshold or the MRPL might be a relevant piece of the puzzle highlighting a 
doping scheme. As an example, the presence of one or several exogenous prohibited substances 
below the threshold limit may have been repeatedly highlighted for an athlete. In this context, each 
individual test does not consist in a doping offense. However, considering a longitudinal perspective, 
this is an interesting indicator of a potentially continuous substance intake and doping behavior. 
Concerning endogenous compounds such as AAS, HGH, human chorionic gonadotropin (hCG) or 
rEPO, concentrations in biological fluids may vary naturally quite significantly, regardless of a 
substance intake. Indeed, the influence of genetic factors, ethnicity, sex, diseases or diet on 
concentration levels and/or carbon isotopic ratio (13C/12C) of AAS molecules has been reported in the 
literature (54, 55). Therefore, a simple concentration measurement may not be sufficient to 
distinguish between the endogenous or exogenous origin of the substance and assessing other 
biomarkers may be necessary. On the one hand an athlete may dope with an endogenous substance 
and yet go unnoticed due to a naturally decreased physiological response to a substance or a 
naturally elevated rate of metabolism resulting in a very short detection window. On the other hand, 
an athlete may show a naturally elevated physiological variability in the concentrations of an 
endogenous compound and meet the criteria of an AAF without any substance intake. The situation 
of the endogenous compounds underlines the need to set individual threshold limits for athletes 
and/or to develop indirect approaches where biomarkers and/or longitudinal monitoring would be 
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more informative to determine the origin of a substance and to increase the detection window. In 
this view, the structured memory would be an invaluable tool to record and structure the 
information for further exploitation and interpretation. 
Accordingly, the ABP aims at the indirect detection of blood doping in the form of blood 
transfusion or the use of erythropoiesis-stimulating agents such as rEPO (56). The hematological 
profile has brought pioneer work as a first step in the development of a logical and inferential 
approach for the interpretation of indirect markers of doping and the determination of individual 
confidence intervals. Indeed, the longitudinal monitoring of multiple blood parameters has initiated 
an important move towards the elaboration of models to interpret data based on transparent and 
sound logical processes. This approach provides a more comprehensive evaluation of observing 
changes in levels and ratios of blood parameters if an athlete is doped rather than clean, by taking 
into account natural variations over time to set personalized and adaptive confidence intervals and 
limits for each athlete (57). As such, the likelihood of observing significant changes in an ABP due to 
blood doping is balanced with several potential natural causes known to modify the erythropoiesis 
and other blood parameters. The athlete’s hematological profile allows refining the targeting of 
athletes by generating alerts when abnormal variations are observed. This is most helpful to increase 
the efficiency of doping controls and to deter blood doping, or to take disciplinary actions when an 
Adverse Passport Finding (APF) is declared (58). 
Likewise, steroidomics, a specific area of metabolomics, aims at the discovery of biomarkers of 
doping with synthetic analogues of AAS or indirect doping with selective estrogen receptor 
modulators (SERMs), aromatase inhibitors or hCG. The steroid profile is constituted of 
concentrations and ratios of endogenous steroidal hormones, as well as related precursors and 
metabolites. The modification of this profile, due to either direct or indirect stimulation, is processed 
through chemometric models taking into account the global steroid metabolism to distinguish 
between a natural physiological condition and steroids misuse (59).  In parallel with the ABP, the 
current development of a urinary steroidal passport integrating the longitudinal monitoring of 
indirect markers of steroids misuse shows promising preliminary results as a way to extend the 
detection window and increase the sensitivity of the tests (59-61). As a consequence, the rate of 
false-negative results may be greatly reduced. Alternatively, the risk of false-adverse analytical 
finding resulting from a single spot blood or urine test may be significantly reduced since such 
indirect approaches can highlight a natural cause to physiological variations exceeding the general 
population limits. Bearing in mind the legal consequences for the athlete and also for the 
laboratories keeping this risk at a strict minimum is mandatory (56). 
Interestingly, the strategy behind the identification of indirect markers allows highlighting 
physiological variations due to doping independently from the type of prohibited substance or 
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method used. This aspect is particularly advantageous for overcoming the limitations of current 
analytical methods and of the legal system in anti-doping as well. Indeed, latency exists between the 
apparition of new therapeutic agents and designer steroids on the market, their detection by anti-
doping authorities and subsequent inclusion to the List. Additionally, there is inertia between the 
annual update of the List and the development of bioanalytical tools to identify and quantify these 
substances. In any case, as the dissimilarity between endogenous compounds and exogenous and 
their exogenous counterparts for therapeutic use tend to decrease with the progresses of 
pharmaceutical science, along with the overall decrease in doses used for doping, direct detection is 
increasingly difficult. 
The hematological and steroidal passports may also serve a further purpose in the evaluation of 
the performance enhancement after substance misuse in order to assess the degree of gravity of a 
doping offense, besides a general overview of the health of the athlete himself. Indeed, an athlete 
doping with low-levels of a prohibited substance might not show a significant physiological response, 
hence benefit from a limited doping effect, as opposed to another athlete involved in heavier misuse. 
With regards to these scientific considerations, the reasoning around doping may evolve towards 
more equitable and flexible justice mechanisms. Actually, compared to criminal law, the anti-doping 
legislation defined by the Code is somewhat rigid since it leaves very little room for a scale of 
penalties based on the gravity and circumstances of the offense. Furthermore, the inequalities 
created by this situation might be reinforced since the 3rd revision of the Code due to come into 
effect in 2015 contains an increase of the two-years ban into a four-years ban and reverses the onus 
of proof thereto. Indeed, where anti-doping authorities had to show aggravating circumstances to 
double the ban from two to four years, athletes will have to demonstrate lack-of-intent for a 
reduction from four to two years. In this context, the situation of recreational drug abuse is subject 
to a large debate within the community as the distinction from regular performance-enhancing 
substances has been abandoned in the final draft that was accepted. A unique sanction will be 
pronounced whether the athlete is using a product for recreative, addiction or doping purposes. 
Conversely, more emphasis on fair judicial proceedings might result from this significant increase in 
the length of the ban. Indeed, due to the gravity of the ban and its serious consequences on the life 
of the athlete, the situation might evolve towards a more flexible and complete evaluation of cases 
brought to court. Accordingly, the principle of proportionality is very likely to be accentuated. As of 
today, predicting accurately the practical evolution of the legal system in anti-doping is impossible. 
Within a tactical intelligence framework, longitudinal and indirect approaches would help to 
support on strong scientific grounds cases of systematic doping and/or doping with substances 
mimicking the function of endogenous compounds. This methodology would also allow refining the 
targeting of athletes to improve the detection of doping. Likewise, within an operational intelligence 
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framework, collating structured memories of athletes containing their longitudinal monitoring would 
help in highlighting trends. Indeed, simultaneous suspicious results across populations of athletes 
may indicate widespread misuse of a specific doping agent or organized doping. 
 
II.2.4. Detection and monitoring of doping phenomena 
Products of Anti-Doping Intelligence may help in the detection and description of a potential, 
emerging or existing, yet unnoticed, trend in the consumption of doping agents. In this perspective, 
the information feeding the organized memory may come from a variety of sources, including 
sociological studies on substance use or abuse, a notice of release from the pharmaceutical industry 
on a new medication with performance-enhancing properties, statistics of law enforcement 
authorities on substance trafficking or the reporting by the medical staff of a sport’s team of a 
growing trend in the consumption of a particular substance, etc. The exploitation of these elements 
stored in the memory in addition to internet monitoring, as described previously, would serve to 
detect substance misuse and to measure variations in the prevalence between sports disciplines, 
individual and team sports, national and international level, genders and also across space and time 
(10). Thereof, internet monitoring and all these studies, surveys and fact sheets would be very 
informative tools to highlight and inform on the size, seriousness and evolution of a problem. 
Through logical processing of these elements, the threat on all different aspects and values of a 
doping-free sport may be assessed and the mechanisms behind doping initiation better understood. 
Actually, prevalence measurement is a recurring topic of underestimated importance and prone 
to analytical and logistical challenges as well as legal limitations. Doped athletes might slip through 
the cracks for a number of reasons, including being tested outside of doping periods or after 
complete elimination of the prohibited substance, or simply not being tested. Conversely, as 
targeting methods keep improving, testing is becoming gradually more intelligent, hence the 
population of athletes subject to anti-doping controls might become less representative of the 
general population. As a result, the statistical significance of prevalence measurements through 
analytical monitoring might be disputable. Then, as mentioned in the ISL, samples must be analyzed 
to detect prohibited substances appearing on the List and no sample may be used for any other 
purpose without the athlete's written consent (6). A complete removal of all identification means 
must be ensured before using samples for research purposes, in order to prevent any traceability 
back to a particular athlete. Since obtaining the consent of the athletes in the first place is extremely 
challenging, this legal mention makes it very difficult for exploratory epidemiological studies in anti-
doping. Therefore, the discovery of trends in the consumption of unlisted or designer products with 
performance-enhancing properties is greatly complicated, especially as an exception to the law is 
always difficult to justify. Removing this rule could bring significant benefices, particularly as an 
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earlier detection of new doping trends and a quicker reaction could be initiated. Likewise, a more 
systematic use of randomized-response surveys might help overcoming these limitations and 
highlighting new trends. The guarantee of anonymity and impunity for the participants usually 
restricts data bias and improves the accuracy of prevalence measurements. 
Anti-Doping Intelligence would improve the gathering of this knowledge through the 
multiplication and logical processing of the input sources mentioned earlier in this section. This 
would be helpful to feed both operational and strategic intelligence in the perspective of evolving 
towards anti-doping programs adapted to the specificities of each situation. Finding a unique 
solution to all problems appears somewhat unrealistic, whereas designing multiple and tailor-made 
strategies may be more fit-for-purpose. This opinion may be perceived as opposite to the principle of 
universality of the Code, which was fundamental to the creation of WADA in the first place and 
ensures the harmonization of the operation of anti-doping. Nevertheless, the limitations of tailored 
rules faced in the pre-WADA and pre-Code era might find a tangible explanation in a fight against 
doping suffering from organization and coordination imperfections at the time. Today’s situation is of 
a different nature, with WADA bringing a clear vision and structured processes to rule anti-doping. 
Therefore, tailor-made anti-doping programs might offer an additional value to the fight as long as 
they remain consistent with the principle of universality underlying the Code. As highlighted during 
the 2013 Anti-Doping in Sports Consensus Meeting held at Home of FIFA in Zurich, cyclists or football 
players are likely to use a different mix of prohibited substances and methods to improve their 
performance as compared to weight-lifters for instance. Therefore, parameters such as training 
periods and the cultural aspect of doping in specific sports have to be taken into account when 
designing testing programs. Quality over quantity was advocated during this meeting, with particular 
emphasis on the need for more intelligent testing. 
In this context, operational intelligence would help in prioritizing areas where anti-doping 
resources are needed to provide a more proactive response to short-circuit potential or emerging 
trends or to address existing problems with innovative actions. Intelligence gathering would serve to 
feed risk assessment processes to identify these specific areas, to evaluate the seriousness of the 
threat or the actual problem and to deploy resources with the optimal cost-benefit ratio. The 
question of prioritization is particularly relevant for governments which are facing a question of 
priority compared to crucial issues, such as healthcare, education, employment or criminality but 
also in very common instances water and food supply, poverty or human rights for example. When it 
comes to allowing financial and human resources, one cannot expect countries with such persistent, 
and sometimes urgent, problems to dedicate resources equivalent to wealthier countries and to 
support equally what appears to be a minor concern. Although it may be argued that an efficient 
anti-doping policy may promote and safeguard good health for the active youth of a nation. 
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Similarly, the strategic intelligence process might result in the inclusion of a substance or 
method to the List or the Monitoring Program, the adjustment of existing law policies, the 
development of a preventive or educational program, or, conversely, the decision not to legislate or 
to cancel the current regulation as the problem under scrutiny may be considered insignificant. 
In addition, an intelligent approach would allow assessing the efficiency of anti-doping programs 
by monitoring the geographical and temporal evolution of a phenomenon. 
 
The following chapter proposes to illustrate and test the phenomenon detection and monitoring 
part of the model by addressing the perceived problem of smokeless tobacco use in sport, in 
particular snus. The concept of Anti-Doping Intelligence being a wide area of research, focus will be 
put on this specific function as a first step towards the practical validation and implementation of the 
theoretical model. 
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III.1. Smoke and smokeless tobacco 
III.1.1. Consumption forms 
A wide variety of consumption patterns exist, from tobacco smoking, in the form of cigarettes, 
cigars or pipes, to smokeless tobacco (ST) products such as snus, moist and dry snuff and chewing 
tobacco.  Actually, snus is a Swedish type of moist snuff, where non-fermented ground tobacco is 
contained in tea bags-like pouches that consumers place between the upper lip and gums (Figure 9). 
 
Figure 9. Snus box and use instructions. 
 
Nicotine replacement therapies also contain this natural compound, as marketed in transdermal 
patches, nasal sprays, inhalers and gums. 
Depending on the type of product, concentrations differ to a reasonable extent. On average, a 
similar content of nicotine is found in cigarette and oral snuff, whereas cigar and chewing tobacco 
contain only about half of this concentration (62). Accordingly, levels of nicotine intake and 
metabolism pathways vary along these different trends of tobacco consumption. When smoked and 
inhaled, nicotine is rapidly absorbed in the lungs, reaching the brain via the bloodstream within 20 s 
(62). On the other hand, there is little to large buccal absorption depending on the pH, which is 
directly related to the type of product (63, 64). Chewing tobacco and snus are buffered to facilitate 
absorption of nicotine through the oral mucosa under its unionized form. A portion of nicotine is 
usually swallowed with saliva and well absorbed in the small intestine. Actually, the intake of nicotine 
from moist snuff (3.6 mg) has been estimated to reach approximately twice the absorbed dose from 
smoking (1.8 mg) (65). Concentration in plasma rises at a slower rate than with smoking and levels 
are declining over a longer period of time (66) (Figure 10). 
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Figure 10. Mean plasma nicotine concentrations at each time point following single use of different tobacco 
products and nicotine gum. Products (nicotine content): • Cigarette (14.6 mg); □ Pouched snus (10.7 mg); ○ 
Loose snus (10.8 mg);  Pouched snus (14.7 mg);  Loose snus (27.1 mg); ◊ Nicotine gum (4.2 mg). The dashed 
line represents the limit of quantification (0.5 ng/mL). Reprinted from (66). 
 
To the best of the author’s knowledge, controlled studies comparing nicotine urinary profiles 
after consumption of smoke and smokeless tobacco products are lacking. 
On a side note, nicotine is also well absorbed through the skin which is the basis for transdermal 
delivery that occurs over a long period of time (67). 
 
III.1.2. Tobacco use and health 
According to the report on smoking prevalence in World Health Organization (WHO) Member 
states, adult daily smoking (male and female) in 2006 ranged between 3-19% in Africa, 4-34% in the 
Americas, 15-29% in South-East Asia, 11-44% in Europe (22% in Switzerland), 6-36% in the Eastern 
Mediterranean region and 10-47% in the Western Pacific region (68). Noteworthy, significantly 
higher numbers are found when considering the adult male population only. As an example, a recent 
survey indicated that 53% of adult Chinese men are daily smokers, while only 2% of the adult women 
currently use smoke tobacco products, resulting in an average prevalence of 28% for the entire adult 
population (69). 
In particular, smoking has been on the decline in Sweden over the last two decades, making it 
the only industrialized country to reach the WHO goal of less than 20% adult smokers (70, 71). 
Nevertheless, ST use has been increasing considerably meanwhile across Scandinavia where snus 
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consumption is traditional. Actually, a prevalence of snus use of 24% in Swedish men and 3% in 
women has been reported in 2010 (70, 72). In comparison, a prevalence of 6.4% among young adults 
between 18-25 and 3.1% among adults over 26 has been reported in the 2010 United States National 
Survey on Drug Use and Health, pairing with the increase of youth ST use in recent years (73). 
Despite public knowledge on toxicity and carcinogenic properties of tobacco smoke 
components, worldwide consumption is responsible for 5 millions of deaths each year, a number 
expected to grow up to 8.3 million by 2030 (68). Noteworthy, tobacco use is the main reason behind 
the escalating burden of disease from the four leading causes of death, including ischaemic heart 
disease, cerebrovascular disease, infections of the lower respiratory system and chronic obstructive 
pulmonary disease (74, 75). In addition, trachea, bronchus and lung cancers mortality is an additional 
major health issue significantly correlated with tobacco consumption. Indeed, due to extremely 
addictive properties, nicotine plays a major role in the repeated exposure to smoke and 
consequently to a variety of carcinogens, among which tar, polycyclic aromatic hydrocarbons (PAH), 
tobacco-specific nitrosamines (TSNA) and pyrolysis products (76-78). 
The treatment of nicotine addiction is a global concern which is considered from different 
perspectives, either supporting smoke cessation programs or preventive and harm-reducing oriented 
smoke regulation policies. Indeed, current strategies focus on different aspects of the problem, 
supporting various approaches, from simple medical advising to pharmacotherapy, or from tax 
increases to implementation of smoke-free environments and distribution of educational material on 
tobacco consumption (68, 79). Harm reduction is a concept based on the assumption that the 
incidence of tobacco-related diseases may be reduced by migrating to less harmful tobacco products 
(80-82). At present, this strategy is best illustrated by a prohibition of smoking in public places 
growing in popularity worldwide, proving efficient in the intent of reducing both direct and passive 
exposure while encouraging smokers to quit. As a consequence, the tobacco industry is finding 
increasing interest to market a diversified range of products to bypass public smoke bans and 
minimize the health risks concerns, in order to maintain tobacco use among existing smokers and to 
recruit new tobacco users (65, 82-87). Accordingly, a solid attempt to increase the attractiveness of 
ST products, in particular snus, is observed throughout Europe and North America (88). However, 
equivalent addictive properties have been observed when comparing smoked and smokeless 
nicotine, which is a serious promoting factor for persistent addiction and for smoking initiation (89, 
90). In addition, despite avoiding respiratory health issues associated to tobacco smoke, 
consumption of ST may be responsible for oral, esophageal and, to a less significant extent, 
pancreatic cancers due to the presence of over 28 carcinogenic constituents, but also heart diseases 
and serious lesions of the oral tissues (91-96). 
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III.2. Nicotine 
III.2.1. Pharmacology 
Nicotine, or 3-(1-methyl-2-pyrrolidinyl)pyridine, is the principal alkaloid found in tobacco leaves, 
where it acts as a natural insecticide. This molecule exhibits a variety of pharmacological properties 
sought-after by consumers and responsible for persistent addiction issues. Among the numerous 
neurotransmitters released in the central nervous system by stimulation of nicotinic cholinergic 
receptors, dopamine is associated with rewarding experiences (97). Promotion of related positive 
reinforcing effects results in vigilance and cognitive function enhancement together with relaxation, 
reduced stress, mood modulation and lower body weight (64, 98). Interestingly, nicotine also triggers 
a significant increase of pulse rate, blood pressure, blood sugar and epinephrine release owing to 
simultaneous stimulant and relaxant properties (67, 99). As a consequence, nicotine addiction 
develops through repeated exposure to experience positive reinforcing effects with relief of 
withdrawal symptoms (97). 
 
III.2.2. Metabolism 
Nicotine is primarily and extensively metabolized in the liver by cytochrome P-450 (CYP) 
2A6/aldehyde oxidase-mediated enzymatic conversion to cotinine (Figure 11) (62, 63, 100, 101). 
Cotinine is further converted to trans-3-hydroxycotinine by CYP2A6-mediated oxidation (102). 
Subsequently, nicotine and cotinine are metabolized into their N-glucuronide conjugates by uridine 
5’-diphosphoglucuronosyltransferase (UGT) 2B10 and UGT1A4, while trans-3-hydroxycotinine is 
transformed into its O-glucuronide conjugate by UGT2B7 (62, 103). Noteworthy, significant inter-
individual differences in the glucuronidation of nicotine and metabolites have been observed. Flavin 
monooxygenase-3 (FMO-3) also converts nicotine into nicotine-N’-oxide and cotinine into cotinine-N-
oxide which are minor metabolites (104). 
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Figure 11. Principal pathways of nicotine metabolism (62, 101). 
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Quantitatively, the simultaneous determination of free urinary nicotine and related metabolites 
has been reported in several studies, allowing estimating the share of each metabolic pathway (Table 
1). 
 
Molecule 
Estimated urinary excretion 
(% of total nicotine dose) 
nicotine 8-10% 
nicotine-glucuronide 3-5% 
cotinine 10-15% 
cotinine-glucuronide 12-17% 
trans-3-hydroxycotinine 33-40% 
trans-3-hydroxycotinine-glucuronide 7-9% 
nicotine-N’-oxide 4-7% 
cotinine-N-oxide 2-5% 
 
Table 1. Summary of the quantitative estimates accounting for nicotine metabolism (62, 100, 105). 
 
Therefore, due to the relatively short half-life of nicotine in urine (about 2 h), investigating 
nicotine metabolites which exhibit a longer half-life is a prerequisite to provide relevant information 
on tobacco consumption. 
While nicotine accounts for approximately 85-95% of the alkaloids content of tobacco leaves, 
anatabine, nornicotine and anabasine are, with respect to this order, the most abundant minor 
alkaloids and excreted in urine unchanged (Figure 12) (62, 93). 
 
  
Figure 12. Chemical structure of minor tobacco alkaloids. 
 
Noteworthy, ~60% of urinary nornicotine come from the metabolism of nicotine, while less than 
40% comes from tobacco (62). 
 
III.2.3. Smokeless tobacco in sport 
A. History of consumption in the United States 
On a historical note, smoking and chewing tobacco among the American Major League Baseball 
(MLB) and Minor League Baseball (MiLB) players dramatically declined during the 1980s, while the 
use of oral snuff rose sharply (106). Indeed, in the late 1980s and throughout the 1990s, investigators 
have reported a prevalence varying between 33% and 45% for MLB players and between 45% and 
55% for National College Athletic Association (NCAA) baseball players (107, 108). In parallel, ~15% of 
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high school baseball players used smokeless tobacco in 1995 (109). These figure and the ~31% 
prevalence among MLB rookie players for the 1999 season indicated that initiation of ST use started 
before joining the professional ranks for most athletes, whether during their college years or in 
minor leagues (108). At the same time, the median age at initiation among MLB and MiLB players 
was ~18 years, with a ~5 years median duration of use (110). Nevertheless, ST consumption is not 
just restricted to baseball, as highlighted in the 2001 NCCA statistics. Indeed, a prevalence of 
smokeless tobacco use reaching ~41% in baseball, ~39% in wrestling, ~35% in ice hockey, ~32% in 
lacrosse, ~29% in football, ~27% in golf, ~25% in water polo, ~20% in soccer, ~17% in track and field, 
~13% in tennis and ~12% in basketball was reported (111). 
Interestingly, this consumption trend had been following a strong association between athletic 
performances and use of ST, as illustrated by the marketing strategy of the tobacco industry during 
this period of time (112). Indeed, rookie and student baseball players have been found to perceive 
the use of ST and the launch of a successful career as intrinsic, regardless of health risks (108). From 
a cultural point of view, baseball players have traditionally been serving as role models in the eyes of 
the youth in America (109). Likewise, the social environment is another significant source of 
influence, as the majority of high school and college men and athletes have been citing friends’ 
consumption of oral snuff  as the primary reason for initiation (113, 114). As a consequence to this 
profound tendency of the youth to mimic the behavior of peer groups or sport idols, millions of 
adolescents across the United States have been taking on a consumption habit responsible for 
persistent nicotine addiction issues and a variety of cancers, heart and mouth diseases (106).  
As a response to the high health risk profile associated with smokeless tobacco, the MLB 
enacted in 1991, and subsequently the NCAA in 1994, a ban on consumption of ST during practices, 
games and team travels for all MiLB, and college players (108, 111). In a joint effort to help both 
professional and college players to reduce and/or quit ST use, a cessation guide was developed by 
the MLB, the Professional Baseball Athletic Trainers Society (PBATS) and the National Cancer 
Institute (NCI) in 1991 (106). This guide was distributed throughout minor and major leagues as well 
as in junior colleges and colleges the following year. 
In taking this action, the baseball world passed on a strong message to the young generations of 
athletes on the potential harm of ST products as well as raising consciousness within society on this 
particular health concern. This is particularly true considering that since the 1970s the tobacco 
industry had been manipulating free nicotine contained in oral snuff products to promote gradation 
of dependence, while deliberately tailoring its marketing strategies to target the youth (65, 88, 115). 
Subsequently, regulation on advertising practices was established in 1998 with the Smokeless 
Tobacco Master Settlement Agreement (STMSA) which stated the “Prohibition on Youth Targeting” 
in both direct and indirect advertising, promotion or marketing of tobacco products (88, 116, 117). 
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Interestingly, this agreement included a prohibition of tobacco brand name sponsorships in any 
football, basketball, baseball, soccer and hockey league. Since that date, young adults have become 
an increasingly important sales target to the point of having the highest rate of dual use of smoke 
and ST compared to adults (118). 
 
B. Doping with smokeless tobacco? Evaluation through Anti-Doping Intelligence 
ST consumption first caught the interest of LAD after hearing testimonies from athletes and/or 
winter sports’ teams at an increasing frequency. According to previous researches, nicotine 
consumption was a popular trend in baseball in the late 80s until the early 2000s, regardless of the 
level of competition, while the almost non-existent information available on other disciplines 
depicted it as a common practice in winter sports (106, 119-121). In particular, recent observations 
within the sport’s community pointed at ice hockey. Considering history and consumption patterns 
of ST throughout the world, North America and Scandinavia are traditional and leading markets for 
the use of moist tobacco pouches, known as snus (70-72). With a strong ice hockey culture, these 
geographical regions appear as a natural and fertile ground for the development of snus 
consumption in this sport. In parallel, recent epidemiological studies inform on the growing 
popularity of ST in society, which is corroborated by commercial facts and figures of the tobacco 
business (114, 115, 122-124). 
Physiological and pharmacological studies on nicotine indicate a potential for performance-
enhancement as a result of stimulant and relaxant properties, as well as almost eliminating adverse 
effects on the respiratory tract with ST as opposed to tobacco smoke (125-128). Indeed, nicotine has 
been vastly reported to improve alerting attention in tasks of vigilance, co-ordination, fine motor 
abilities, memory and cognitive performance, in particular at small to intermediate levels of nicotinic 
stimulation (125, 127, 129-132). Cognition being an important factor in sport, such optimization of 
neurobiological function might benefit a variety of sports including sport games or track and field 
(133, 134). The increased pain tolerance experienced after nicotine intake might also be an 
interesting advantage (125). Likewise, an improvement of 17±7% in delay to exhaustion due to 
moderate-intensity exercise has been shown after nicotine administration (129). Similarly to caffeine, 
nicotine seems to delay central fatigue as impaired central drive is an important factor contributing 
to fatigue during exercise (133). Nonetheless, there is a debate around this topic as surveys during 
the 1990s did not point out performance-enhancement properties of nicotine for sport practice 
(109). However, these assumptions were generally based on performance statistics of athletes rather 
than controlled studies after nicotine administration. 
Nicotine did not appear on the WADA Prohibited List and Monitoring Program when this 
research was initiated in 2009 and still does not appear on the current List despite satisfying all three 
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inclusion criteria (4, 5). Indeed, this substance may enhance sport performance in the first place. 
While health consequences are mainly related to the carcinogenic compounds contained in tobacco 
or/and coming from the combustion process, nicotine triggers strong addiction mechanisms 
responsible for repetitive exposure to these harmful chemicals. Therefore, the highly addictive 
properties of nicotine represent a serious health threat for the athlete. Since the risk assessment by 
public authorities does not lead to making tobacco or nicotine illegal in countries around the world, 
WADA raised the concern that the second criterion may not be applicable to ban tobacco in sport. 
However, this argument is not really relevant as the majority of banned substances are therapeutic 
agents which are not illegal in society, but at most under controlled medical use or available in 
pharmacies on presentation of a prescription. Eventually, the negative image associated with 
tobacco consumption may also alter the spirit of sport. 
When collating this information and considering the absence of any regulation on nicotine use in 
sport, raising interest on the consumption of ST in sport is legitimate for what appears to be an 
attractive drug from a doping perspective (Figure 13). 
 
 
Figure 13. Reasoning mechanism on the interest towards potential doping with ST and related questions 
relevant to Anti-Doping authorities for decision-making on this topic. 
 
Nonetheless, large-scale comprehensive surveys on nicotine consumption in sport are lacking 
and to ascertain the frontier between recreational use of a social drug and doping purpose is 
difficult. Therefore, the following studies propose to illustrate the use of Forensic Intelligence to 
address social drugs in sport, and more specifically nicotine consumption through ST.  
Acquisition of fresh information was essential to feed the logical process to obtain a more 
complete picture of the phenomenon. As a first step, developing and validating analytical chemistry 
 47 CHAPTER III | SMOKELESS TOBACCO IN SPORT 
 
tools was a necessary prerequisite to be able to highlight and measure nicotine consumption by the 
athletes. Further on, prevalence studies could be conducted to collect epidemiological data. These 
observations were structured and collated with the information carried by testimonies, previous 
prevalence studies and pharmacological properties of nicotine already integrated into the memory. 
Afterwards, since sociological data were required to better understand ST consumption mechanisms, 
a behavioral study based on the randomized-response survey model was designed. In summary, the 
general idea behind ST studies was to detect, measure, follow and gain knowledge on this 
phenomenon following an intelligence approach and, ideally, to support anti-doping authorities in 
decision-making on tobacco consumption in sport. 
 
III.3. Specific projects on smokeless tobacco in sport 
During the first step in the elaboration of an intelligence-driven approach for the detection of 
phenomenon, a prevalence study was conducted during the 2009 Ice Hockey World Championships 
held in Switzerland (original paper in Appendix V.2.7). The idea to qualify and quantify nicotine 
consumption in ice hockey was initiated by recurrent testimonies from athletes, team coaches and 
sports doctors on snus consumption paired along the significant prevalence of snus use in countries 
with a strong ice hockey culture, such as Scandinavia for instance.  
Then, as the phenomenon appeared to be worth further investigations due to the alarming 
statistics highlighted during this competition, a second prevalence study was conducted to inform on 
nicotine consumption throughout 2010 across all sports disciplines (original paper in Appendix V.2.6). 
Accordingly, every IC doping test performed on Swiss athletes or athletes taking part to a sports 
event in Switzerland was analyzed to provide a picture of the phenomenon as a whole and in each 
different discipline. 
Afterwards, as the prevalence appeared to be significant in numerous of sports, a clinical study 
was set up to determine nicotine metabolism after smoke or ST administration (protocol in Appendix 
V.3). The purpose of this project was to develop analytical tools and statistical models based on the 
metabolic profile of nicotine to distinguish between these different forms of tobacco use. As a result, 
more precise statistics on ST consumption could be gathered in future monitoring surveys in order to 
inform on the size and evolution of snus use rather than nicotine consumption regardless of the form 
of exposure. Likewise, a metabolic-based model could allow assessing specific cases of interest.  
Eventually, a sociological study was designed to investigate on the purpose behind snus 
consumption in ice hockey and its perception by athletes, whether from performance-enhancement 
or recreational perspectives. Accordingly, every ice hockey player engaged in a Swiss National or 
 48 CHAPTER III | SMOKELESS TOBACCO IN SPORT 
 
Regional League and every junior player will be asked to fill in a questionnaire addressing nicotine 
consumption. 
 
III.3.1. Prevalence of nicotine during the ‘09 Ice Hockey World Championships 
A. Introduction 
During the first step in the elaboration of an intelligence-driven approach for the detection of 
phenomenon, a prevalence study was conducted during the 2009 Ice Hockey World Championships 
held in Switzerland to qualify and quantify nicotine consumption in top-level ice hockey. 
A sample preparation protocol and an analytical method for the identification and quantification 
of nicotine and unconjugated metabolites in urine samples (cotinine, trans-3-hydroxicotinine, 
nicotine-N’-oxide and cotinine-N-oxide) by liquid chromatography-tandem mass spectrometry (LC-
MS/MS) were developed and validated in-house. 
The results of this research have been published and the original paper may be found in 
Appendix V.2.7 (135). 
 
B. Experimental 
The analytical method for the simultaneous determination and quantification of nicotine and its 
four main unconjugated metabolites in urine involved liquid-liquid extraction (LLE) followed by LC-
MS/MS analysis in Hydrophilic Interaction Chromatography (HILIC) mode. Apart from a recent 
publication on nicotine, cotinine and trans-3-hydroxycotinine analysis, HILIC columns had never been 
previously used for such purpose in real biological samples, in particular when including nicotine-N’-
oxide and cotinine-N-oxide (136). Nevertheless, this methodology is primarily dedicated to the 
analysis of polar compounds, such as basic molecules and related metabolites excreted in urine (137, 
138). Owing to the nature of screening procedures for doping agents, a rapid and simple extraction 
procedure was favored for this prevalence study. 
 
B.1. Sample preparation 
Urine samples clean-up is based on a method previously published and adapted to our particular 
needs and matrix (139). An aliquot of urine (1 mL) was spiked with 10 L of 10 g/mL deuterated 
internal standard (IS) solution (d4-nicotine, d3-cotinine and d3-trans-3-hydroxycotinine) and diluted 
with 1 mL phosphate buffer (0.2 M, pH 7.0) prior to vortex mixing. LLE was performed with 2.5 mL 
chloroform: propan-2-ol (95:5, v/v) for 10 min using a rotator unit. After centrifugation for 5 min at 
2500 rpm, the organic layer was evaporated to dryness under a gentle air stream at 50 °C and 
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reconstituted in 1 mL ACN: ammonium formate (10mM, pH 3.0) (98:2, v/v) prior to LC-MS/MS 
injection. 
 
B.2. LC conditions 
Separation was carried out on a LC-MS/MS system using a Rheos 2000 CPS-LC system pump 
(Flux Instrument, Basel, Switzerland) and an HTS Pal autosampler (CTC analytics AG, Zwingen, 
Switzerland). Hydrophilic Interaction Chromatography was performed on a Phenomenex Luna® HILIC 
column (150 mm × 3.0 mm, 5 m) (Brechbühler AG, Schlieren, Switzerland) with a guard column 
SecurityGuard™ HILIC (4 x 2.0 mm) (Brechbühler AG, Schlieren, Switzerland) added to the analytical 
column. The column temperature and the autosampler tray were set at 30 °C and 4 °C, respectively. 
Mobile phase consisted of ACN (A) and 10 mM ammonium formate (pH 3.0) buffer (B) with a flow 
rate set at 0.3 mL/min, while partial loop injection volume was 10 L with a 20L loop. The initial 
mobile phase condition was 98% A for 3 min, which was decreased linearly to 35% and held from 10 
to 13 min, then increased back to 98% to re-equilibrate the column from 13.1 to 16 min.  
 
B.3. Linear Trap Quadrupole-MS parameters 
Analyses were performed using a linear ion trap mass spectrometer LTQ-MS (ThermoFinnigan, 
San Jose, CA, USA) equipped with an atmospheric pressure ionization (API) interface, Ion MAX™, 
operated in positive ESI mode. MS operating conditions were set as follows: spray voltage = 5.0 kV; 
heated capillary voltage and temperature of 10 V and 320 °C, respectively; isolation width of 1.5 Da; 
activation time = 30 ms; activation q of 0.250 and scan time was fixed at 30 ms. Sheath gas, auxiliary 
gas and sweep gas (nitrogen) were set at 20, 5 and 1.5, respectively. 
 
B.4. Identification criteria 
Identification criteria were defined according to the WADA Technical Document addressing 
qualitative assays (140). The retention time (tR) tolerance window corresponding to the analyte and 
the quality control (QC) of the same batch must be within the range of ± 2%. Also, three diagnostic 
ions are required, which may include the precursor ion, with an intensity  5% of the most intense 
diagnostic ion of the MS/MS spectrum. Eventually, a  Signal-to-Noise ratio  3 must be be observed, 
with a relative intensity of any of the ions not differing by more than 10% (absolute) or 25% (relative) 
from the QC urine. 
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B.5. Method validation 
Calibration curves 
Experiments were conducted following the guidelines on bioanalytical method validation from 
the US Food and Drug Administration (FDA) and the recommendation of the 3rd American 
Association of Pharmaceutical Scientists (AAPS)/FDA Bioanalytical Workshop in 2006 (141, 142). 
A pool of six urine samples from nicotine-abstinent individuals who had not been exposed to 
environmental smoke within the last 5 days was prepared to obtain negative urine (Uneg) for the 
validation process. 
Also, according to the pharmacological effects of nicotine and keeping in mind a doping 
perspective, only recent consumption of nicotine was of relevant interest. Indeed, trace levels in the 
1 ng/mL scale would not provide meaningful quantitative information on the consumption behavior. 
Thus, in order to ensure statistical significance for further discrimination between recreational, 
environmental or doping use, choosing a concentration of 10 ng/mL for the lowest calibrator through 
the validation procedure looked appropriate to ensure quality quantitative results while maintaining 
minor bias. 
Therefore, the calibration was established over the 10-10’000 ng/mL range for nicotine, cotinine 
and trans-3-hydroxycotinine and 10-5’000 ng/mL range for nicotine-N’-oxide and cotinine-N-oxide. A 
set of three validation series was achieved, with calibration standards at six concentration levels (k = 
6) and validator standards (QC) at four concentration levels (k = 4) prepared in triplicate (n = 3) each 
time. Calibration curves were built from the peak area ratio of nicotine and metabolites to d4-
nicotine for nicotine, d3-cotinine for cotinine and d3-trans-3-hydroxycotinine for trans-3-
hydroxycotinine, nicotine-N’-oxide and cotinine-N-oxide. Accuracy was defined as the closeness of 
agreement between the theoretical and the average measured concentrations. Precision expressed 
the closeness of agreement between a series of measurements obtained from multiple sampling of 
the same homogeneous sample under the prescribed conditions. Repeatability and intermediate 
precision are two of the three different levels of precision. Repeatability was expressed as the 
relative standard deviation (RSD) of the ratio of the intra-day standard deviation and the theoretical 
value at each concentration level (143). Intermediate precision was expressed as the RSD of the ratio 
of the inter-day standard deviation on the theoretical value at each concentration level. An accuracy 
profile was built for each analyte, combining accuracy and intermediate fidelity variance in the 
dosing range (144, 145). Data were processed and reported with Xcalibur LCquan package software 
from ThermoFinnigan and calculation were performed on Excel 2007 from Microsoft.   
The lower limit of quantification (LLOQ) was determined as the lowest QC sample with an 
acceptable accuracy, repeatability and intermediate precision fitting for purpose. Quantitative 
analysis of nicotine and metabolites in real urine samples was performed using a three-points 
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calibration curve determined and fitted by a linear least-squares regression of the peak area ratios 
between the analyte and the IS versus concentrations. The limit of detection (LOD) was defined as 
the concentration that produced a signal three times above the noise level of a blank urine 
preparation. 
 
Selectivity 
Influence of endogenous matrix compounds was determined by analyzing urine samples from 6 
individuals certified as negative (< LOD) for nicotine and metabolites. Each sample was extracted in 
triplicate to highlight the presence of potential interfering matrix compounds within selected 
tolerance windows. 
Accordingly, influence of exogenous xenobiotics was determined by analyzing urine samples 
from over 250 individuals with different nicotine consumption habits who reported the use of very 
various substances appearing on the 2009 Prohibited List and Monitoring Program. 
 
Carry-over 
Carry-over was evaluated correspondingly by injecting a blank urine sample subsequently to the 
analysis of the highest calibrator. This experiment was conducted in triplicate. 
 
Matrix effects 
Matrix effects on the ionization response and extraction efficiency were further evaluated along 
the recommendations published elsewhere (146). A neat solution was fortified at low, medium and 
high concentration in the initial mobile phase ACN: ammonium formate 10 mM (pH 3.0) buffer (98:2) 
(a), while a set of 6 negative urines was also fortified in duplicate prior to extraction (b) and another 
set of blank urine specimens was extracted and fortified only after (c). By comparing the absolute 
peak areas of two sets of solutions, matrix effect and extraction efficiency can be evaluated, as 
reported below (Eqs. (1) - (2)). 
Matrix effect (ME) = c/a (1) 
Extraction efficiency (RE) = b/c (2) 
 
Stability 
The effect of storage conditions was studied by performing a longitudinal stability assay. Analyte 
stability was evaluated by monitoring the influence of successive freeze and thaw cycles of QC urine 
samples at low, medium and high concentrations over a period of six months. As real urine samples 
were stored at -20 °C in a sealed box since their collection, the QCs were handled likewise and 
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defrosted at ambient temperature twice a month for LC-MS/MS analysis. The initial integrated peak 
area was defined as 100%. 
 
C. Results and Discussion 
C.1. Method development 
 LC-MS/MS analyses 
A complete separation of nicotine and metabolites in urine specimens was achieved by 
hydrophilic interaction chromatography using a gradient of ACN (A) and 10 mM ammonium formate 
(pH 3.0) buffer (B) with a flow rate set at 0.3 mL/min (Figure 14). Indeed, HILIC mode allowed 
successfully isolating each analyte by providing adequate retention of polar compounds and 
excellent peak shape. Sensitivity was also optimized since using a mobile phase highly enriched in 
polar organic solvent ensures an efficient ionization towards the molecules of interest (137). 
Likewise, reduced endogenous matrix interferences resulted in very clean chromatograms and a high 
throughput was obtained due to the feasibility of using a higher flow rate. 
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Figure 14. LC-MS/MS chromatograms of a blank urine (A) compared to a urine specimen containing nicotine, 
cotinine, trans-3-hydroxycotinine, nicotine-N’-oxide and cotinine-N-oxide at a concentration of 10 ng/mL (B), 
both with IS spiked at 100 ng/mL. A chromatogram of a urine sample from a hockey player containing the 
above mentioned metabolites at 1’074, 1’415, 3’739, 2’586 and 459 ng/mL, respectively, is also depicted (C). 
Quantification ion transitions are in bold. 
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Repeatability of the retention times (tR) was evaluated by calculating mean values variability 
over the set of three validation series which consisted in 45 extracted samples (Table 2). The RSD 
obtained were found satisfactory for all the compounds of interest, ranging from 1.8 - 4.1%. 
*Quantification ion transitions are in bold. 
Table 2. SRM parameters and retention times of the analytes. 
 
Direct infusion of individual standard solutions, with a flow rate and mobile phase composition 
corresponding to the elution time from the LC column, allowed optimization of tandem mass 
spectrometry parameters. Gas streams, spray voltage, heated capillary voltage and temperature, 
isolation width and compound specific normalized collision energies were manually tuned, resulting 
in a high sensitivity fragment spectra with a precursor ion response < 10% in abundance. SRM 
transitions, collision energies and retention times for each analyte are provided in Table 2. 
 
 LLE 
Sample preparation in dope testing favors time and cost efficient procedures providing 
satisfactory matrix clean-up and recovery. Thus, the selective extraction protocol for urine samples 
used in this work was performed with a single LLE. Nicotine and metabolites were neutralized with 
phosphate buffer at pH 7.0, triggering the extraction with chloroform: propan-2-ol (95:5, v/v). 
Extraction was followed by evaporation of the organic phase and reconstitution in the initial mobile 
phase mixture. This simple, cost and steps-limited methodology provided very clean extracts of urine 
samples containing nicotine and metabolites. Noteworthy, a batch of 50 items could be prepared 
within 1 h, allowing a significant workflow of analysis. 
RE ranged from 70.4 to 100.4% depending on the analyte, with evidence of good repeatability 
(RSD < 15%), and showed only slight dependency on the concentration level (Table 3). 
Molecule SRM transition (m/z)* Collision energy (eV) tR (min) 
nicotine 163  132, 120, 106 25 3.18 
d4-nicotine 167  136, 124, 110 26 3.24 
cotinine 177  146, 98, 80 28 1.93 
d3-cotinine 180  146, 101, 81 28 1.93 
trans-3-hydroxycotinine 193  134, 118, 80 26 2.13 
d3-trans-3-hydroxycotinine 196  134, 89, 80 26 2.14 
nicotine-N’-oxide 179  132, 130, 117 22 7.34 
cotinine-N-oxide 193  134, 96, 98 26 2.56 
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Table 3. Recovery and related RSD of nicotine and metabolites at low, medium and high concentrations (n = 5). 
 
Indeed, RE for trans-3-hydroxycotinine was below what was obtained for the other metabolites. 
This may result from the pKa of trans-3-hydroxycotinine being much lower compared to the pH of 
the phosphate buffer. 
 
C.2. Assay validation 
 Calibration curves 
Concentration ranges were initially determined according to expected levels in urine for nicotine 
and metabolites, while considering both the pharmacological effects of nicotine and a doping 
perspective which focuses on recent consumption only (147, 148). Thus, in order to ascertain 
statistical significance for further discrimination between recreational, environmental or doping use, 
a LLOQ of 10 ng/mL proved to ensure very accurate quantification. 
Determination of the best calibration was performed with the evaluation of different curves 
fitting. Combining accuracy and intermediate fidelity variance allowed building a profile of 
confidence interval in the dosage range for each target compound (144, 145). According to these 
accuracy profiles, unweighted linear least-squares regression was found to provide the highest 
quality results and was chosen for quantification purpose. Due to the linear response, calibration 
standards were subsequently reduced to LLOQ, medium and ULOQ concentration levels (k = 3) and 
QCs to low, medium and high concentration levels (k = 3) with accuracy profiles of comparable 
quality (Figure 15). 
Molecule 
Concentration (ng/mL) Recovery (%) RSD (%) 
Low Medium High Low Medium High Low Medium High 
nicotine 10 5’000 10’000 95.2 93.4 89.9 3 2 3 
cotinine 10 5’000 10’000 99.8 97.6 95.7 9 5 1 
trans-3-hydroxycotinine 10 5’000 10’000 70.4 71.6 73.1 5 3 2 
nicotine-N’-oxide 10 2’500 5’000 82.3 83.1 83.2 3 1 0 
cotinine-N-oxide 10 2’500 5’000 76.6 80.5 82.7 0 0 1 
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Figure 15. Absolute accuracy profiles for nicotine and metabolites. The solid line indicates the accuracy and the 
dashed lines represent the accuracy calculated as confidence interval (145). The dotted lines depict the 
acceptance limits of ± 30 %. 
 
Indeed, accuracy, repeatability and intermediate precision assessments met the guidelines for 
bioanalytical method validation over the assay range (Table 4). Noteworthy, coefficient of 
determination (R2) corresponding to the initial calibration curve for each compound (k = 6) were 
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greater than 0.95, while R2 with a reduced number of calibrators (k = 3) were greater than 0.99. This 
significantly improved the applicability of this method, allowing a better workflow and simplified 
calibration. 
Table 4. Assay validation parameters for nicotine and metabolites (n = 3). 
 
Therefore, suitability of direct quantification of nicotine and metabolites in urine with this LC–
MS/MS method was proven, in particular for nicotine, cotinine and trans-3-hydroxycotinine along 
with nicotine-N’-oxide and cotinine-N-oxide at concentration ranges of 10 - 10’000 ng/mL and 10 - 
5’000 ng/mL, respectively. 
Also, the LOD was found to stand around 500 pg/mL for all compounds. 
 
 Selectivity 
Selectivity tests towards endogenous matrix compounds were conducted on 6 different urine 
samples obtained from nicotine-abstinent individuals who had not been exposed to environmental 
smoke within the last 5 days. After extraction in triplicate followed by LC-MS/MS analysis, no 
interfering endogenous molecules were observed within selected scan windows since ion 
identification criteria, including retention times, ion transitions and ion ratios, were not met (140). 
Likewise, assessment of potential influence of exogenous xenobiotics was performed on a set of 
over 250 urine samples collected from individuals of the general population who reported joint 
exposure of nicotine and different substances present in the 2009 Prohibited List and Monitoring 
Program. Noteworthy, influence of stimulants most commonly found in urine of hockey players was 
Molecule 
Concentration 
(ng/mL) 
Accuracy 
(%CV) 
Precision 
Repeatability 
(%CV) 
Intermediate 
precision (%CV) 
nicotine 10 98.4 7.6 8.1 
 
5’000 92.5 6.5 6.6 
 
10’000 91.8 6.8 6.9 
  
   
cotinine 10 105.0 6.4 9.2 
 
5’000 85.5 6.9 7.2 
 
10’000 109.1 2.7 6.6 
  
   
trans-3-hydroxycotinine 10 96.6 7.6 7.8 
 
5’000 89.6 6.0 7.3 
 
10’000 96.1 5.6 6.2 
  
   
nicotine-N’-oxide 10 102.4 5.5 5.3 
 
2’500 96.8 9.4 9.9 
 
5’000 94.3 7.7 8.8 
  
   
cotinine-N-oxide 10 103.9 5.3 5.7 
 
2’500 101.1 5.4 5.9 
 
5’000 89.9 4.6 6.7 
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evaluated, among which caffeine and pseudoephedrine. Again, after extraction and LC-MS/MS 
analysis, no interfering exogenous xenobiotics were observed within selected scan windows 
according to the criteria mentioned earlier. 
 
Carry-over 
Carry-over was evaluated accordingly, after injection of the highest calibrator (10’000 ng/mL for 
nicotine, cotinine and trans-3-hydroxycotinine and 5’000 ng/mL for nicotine-N’-oxide and cotinine-N-
oxide), followed by the analysis of a blank urine sample. This procedure was repeated three times 
successively. None of the target compounds were detected, demonstrating the absence of any carry-
over effect. 
 
Matrix effect 
ME evaluation by comparison of the signals observed in urine and in the neat solution indicated 
ion enhancement or suppression depending on the target analyte and concentration. Indeed, 
nicotine, d4-nicotine, nicotine-N’-oxide and cotinine-N-oxide showed significant ion enhancement at 
low, medium and high concentrations, while cotinine, d3-cotinine, trans-3-hydroxycotinine and d3-
trans-3-hydroxycotinine showed substantial ion suppression at low concentration (data not shown). 
According to the good repeatability of these assessments (RSD < 15%), along with the satisfactory 
sensitivity and selectivity of the method, ME influence on the results quality was not significant. 
 
 Stability 
The influence of storage conditions was evaluated by performing a longitudinal stability assay of 
QC samples every two weeks over a period of six months. Indeed, these samples experienced freeze 
and thaw cycles involving successive storage at -20 °C in a complete dark environment and defrost at 
room temperature, corresponding to storage and analysis conditions during this study. 
Referring to the limited variation observed in the peak areas (RSD < 15%), the storage conditions 
described previously ensured a high stability of all analytes over this particular period of time. 
 
D. Application to the Ice Hockey World Championships samples 
As part of regular doping control protocols during the 2009 Ice Hockey World Championships 
held in Switzerland, urine samples were collected shortly after every game on two players of each 
team (n = 72). After approval by the International Ice Hockey Federation (IIHF) and the Swiss National 
Anti-Doping Agency (Antidoping Switzerland or ADCH) and as required by the 2009 International 
Standards for Laboratories (ISL), article 19 of the World Anti-Doping Code and articles 24-27 of the 
UNESCO Convention against doping in sport, a minimum storage period of three months and 
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complete removal of identification means were ensured prior to use of these samples for research 
purpose (3, 6, 149). Noteworthy, storage time did not exceed six months. 
Compounds of interest were quantified in duplicate using a three-point calibration curve 
together with three urine-based QCs, as described previously. Also, a qualitative value was assigned 
to target analytes metabolites detected in the sub-LLOQ concentration range, namely traces. 
Concentrations distribution for nicotine and metabolites as quantified in urine specimens are 
illustrated in Figure 16.  Nicotine, cotinine, trans-3-hydroxycotinine, nicotine-N’-oxide and cotinine-
N-oxide concentrations ranged between 11 – 19’750 ng/mL, 13 – 10’475 ng/mL, 10 – 8’217 ng/mL, 
11 – 3’396 ng/mL and 13 – 1’640 ng/mL, respectively. 
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Figure 16. Concentrations distribution for nicotine and metabolites. The solid red line indicates the cumulative 
percentage. 
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Traces of nicotine, cotinine, trans-3-hydroxycotinine, nicotine-N’-oxide and cotinine-N-oxide 
were detected in 87%, 91%, 94%, 97% and 97% of samples, respectively (Table 5). Noteworthy, at 
least one of the three major metabolites was present in every sample. These findings suggest that 
every athlete was exposed to nicotine, either environmentally or from active consumption, during 
the competition period. Such results should be carefully interpreted regarding prevalence studies on 
smoking in society and on environmental tobacco exposure (ETS) among non-smokers. Indeed, 
smoking prevalence has been reported by WHO as ranging from 15 - 44% depending on the country 
participating to the 2009 IIHF World Championships (68). These numbers are usually higher for the 
male population only. Actually, the sixteen participating national teams were Austria, Belarus, 
Canada, Czech Republic, Denmark, France, Finland, Germany, Hungary, Latvia, Norway, Russia, 
Slovakia, Sweden, Switzerland and the United States. In 2009-2010, daily snus consumption 
prevalence among the countries in competition was the highest for Sweden and Norway, concerning 
24% and 33% of adult males, respectively (70, 72, 128). Also, ETS for a period of at least one hour per 
day reached 21% in Switzerland, which hosted the competition (150). However, both facts may 
explain only parts of such extensive nicotine exposure when considering that athletes are 
significantly less likely to smoke or to be exposed to ETS than the general population, in particular 
within the confined environment of such a major competition. 
Analyte 
Concentration range 
x  LOD x  LLOQ Active exposure 
nicotine 87.5% 51.4% 36.1% 
cotinine 91.7% 43.1% 36.1% 
trans-3-hydroxycotinine 94.4% 68.1% 40.2% 
Cumulative exposure 100% 83.3% 52.7% 
    nicotine-N'-oxide 97.2% 58.3% 44.4% 
cotinine-N-oxide 97.2% 51.4% 38.8% 
 
Table 5. Prevalence of IIHF urine samples exposed to nicotine or metabolites depending on the concentration 
range (n = 72). 
 
Furthermore, above LLOQ levels of the previously mentioned compounds were measured in 
51%, 43%, 68%, 58% and 51% of samples, respectively. One of the three major metabolites was 
detected at such concentrations in 83% of samples. According to the pharmacokinetics of nicotine, 
exposure may have occurred within the last three days previous to the games for approximately 
eight ice hockey players out of ten (151). 
Prevalence of nicotine consumption, in the form of smoke or smokeless nicotine, close to and/or 
during the games was evaluated by hypothesizing conservative concentration limits for active 
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consumption (50 ng/mL for nicotine, cotinine and trans-3-hydroxycotinine) (151, 152). Also, chances 
of exposure to serious environmental smoke within the few hours prior to games of such importance 
were excluded. Accordingly, active nicotine use was highlighted in 36% - 40% of samples, depending 
on the target compound (Table 5). Noteworthy, at least one of the three major metabolites was 
present at such levels in 53% of the urine samples, emphasizing a significant prevalence of nicotine 
consumption amongst ice hockey players close to and/or during the games. 
Interestingly, two samples presented highly elevated nicotine concentrations exceeding 10’000 
ng/mL. Such acute exposure to nicotine is hardly achievable for a regular consumer (148, 153). 
Considering the detrimental respiratory effects due to extensive smoking prior to sport practice and 
as players do not smoke during games, smokeless nicotine use is the most likely hypothesis and a 
doping purpose may be hypothesized (154-157). This is also supported by the relatively short half life 
of nicotine. Thus, according to the quantitative measurements, the likelihood of smokeless nicotine 
use for these two samples is very high. However, due to the lack of clinical studies and statistical 
models to address the metabolic-based distinction between different forms of nicotine consumption, 
this hypothesis could not be verified for these two samples or be evaluated for samples with lower 
concentrations of nicotine and metabolites. Likewise, studies on the relationship between nicotine 
levels and doping are missing, hence the careful assumptions made here. 
 In the context of understanding use of smoked tobacco or ST from concentration data, the 
question of steady-state concentrations in chronic smokers is important. According to the literature, 
only limited accumulation has been observed for plasma levels of nicotine after multiple doses (158). 
Despite the lack of consistent urinary data on this topic, a similar situation is very likely to be 
observed. Likewise, night abstinence allows reducing nicotine down to very low levels, even for 
chronic users (62, 151, 159). Therefore, the issue of steady-state nicotine concentrations was not 
considered as a significant bias for the interpretation of the data. 
 
E. Conclusion 
In summary, this work highlighted an alarming prevalence of active nicotine consumption of 
nicotine during ice hockey games at top-level far superior to the prevalence of smoking and ST use in 
society. As this preliminary study focused on a single event and discipline, regardless of the type of 
product and the recreational or doping character of nicotine use, a larger-scale study was required to 
assess the extent of this phenomenon. 
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III.3.2. Prevalence of nicotine in sports during 2010 
A. Introduction 
Considering these preliminary results, a one-year monitoring study was conducted to assess the 
prevalence of nicotine consumption across all sports disciplines tested IC by ADCH over a one-year 
period of time covering 2010 and 2011. 
In order to deal with a very high volume of samples, a straight-forward dilute-and-shoot (DS) 
sample treatment procedure and a ultra-high pressure liquid chromatography-triple quadrupole 
mass spectrometry (UHPLC-TQ-MS/MS) method were developed for the identification and 
quantification of nicotine, its major metabolites (cotinine and trans-3-hydroxicotinine), minor 
metabolites (nicotine-N’-oxide and cotinine-N-oxide) as well as minor tobacco alkaloids (anabasine, 
anatabine and nornicotine). 
Again, the results of this research have been published and the original paper may be found in 
Appendix V.2.6 (160). 
 
B. Experimental 
The previous analytical method for the simultaneous determination and quantification of 
nicotine and its four main unconjugated metabolites in urine involved liquid-liquid extraction (LLE) 
followed by LC-MS/MS analysis in Hydrophilic Interaction Chromatography (HILIC) mode. While this 
approach was found satisfactory for the analysis of a small number of samples, a more time- and 
cost-efficient method with comparable, if not superior, sensitivity and selectivity was required for a 
year-long monitoring of nicotine use. Therefore, a semi-automated DS treatment was developed to 
replace the LLE procedure and the HILIC method was transposed from the LC-MS/MS system to a 
UHPLC-TQ-MS/MS instrument. 
 
B.1. Sample preparation 
An aliquot of urine (20 L) was loaded by a Freedom EVO 150 pipetting robot (Tecan Systems, 
Männedorf, Switzerland) on a 96-well plate, spiked with 20 L of deuterated internal standard (IS) 
solution (d4-nicotine and d4-anatabine at 250 ng/mL, d3-cotinine and d3-trans-3-hydroxycotinine at 
50 ng/mL in ACN) and diluted with 760 L ACN prior to vortex mixing, corresponding to a 40-fold 
dilution. After centrifugation for 5 min at 2500 rpm, the supernatant was transferred to another 96-
well plate with the pipetting robot and followed by UHPLC-MS/MS injection. 
When concentration of a target analyte was determined as superior to the upper limit of 
quantification (ULOQ), a second aliquot of urine was prepared likewise but spiked with 40 l of IS 
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solution and diluted with 1’540 l of ACN, resulting in an 80-fold dilution. Eventually, measured 
concentration was multiplied by 2 after UHPLC-MS/MS analysis. 
 
B.2. UHPLC conditions 
Separation was carried out on an Acquity UPLC System (Waters, Milford, USA) with a Waters 
Acquity UPLC BEH HILIC column (2.1 x 50 mm, 1.7 m) preceded by a Waters Acquity UPLC BEH HILIC 
VanGuard pre-column (2.1 x 5 mm, 1.7 m). Column and autosampler tray temperatures were set at 
30 °C and 10 °C, respectively. Mobile phase consisted of ACN (A) and 10 mM ammonium formate (pH 
3.0) buffer (B) with a flow rate set at 800 L/min. Initial mobile phase was 99% A held for 0.7 min, 
decreased linearly to 75% over 1.9 min in a first step and then to 40% over 0.35 min. The column was 
washed during 0.25 min and mobile phase increased back to 99% to re-equilibrate the system for 1.8 
min. Injection volume was fixed at 2 L in full loop mode. 
 
B.3. Triple Quadrupole-MS parameters 
Analyses were performed using a Waters Xevo™ TQ-S triple quadrupole mass spectrometer 
equipped with an electrospray ionization (ESI) source operating in positive mode. MS operating 
conditions were set as follows: desolvation gas flow set at 600 L/h at a temperature of 550 °C, 
capillary voltage at 3.0 kV in positive mode, cone voltage and collision energies optimised for each 
compound (Table 6). The source temperature was 150 °C, the cone gas flow was set to 150 L/h and 
the collision gas flow was 0.15 mL/min. 
*Quantification ion transitions are in bold. 
Table 6. MRM parameters and retention times of the analytes. 
 
Molecule MRM transition (m/z)* 
Collision 
energy (eV) 
Cone 
voltage (V) 
tR (min) 
nicotine 163  132, 117, 84 15 18 2.04 
d4-nicotine 167  136, 134, 121 20 20 2.05 
cotinine 177  146, 98, 80 16 15 1.02 
d3-cotinine 180  146, 101, 81 20 20 1.04 
trans-3-hydroxycotinine 193  134, 86, 80 20 16 0.97 
d3-trans-3-hydroxycotinine 196  134, 89, 80 20 20 0.99 
nicotine-N’-oxide 179  132, 130, 117  14 10 2.75 
cotinine-N-oxide 193  134, 96, 79 18 14 1.90 
anabasine 163  146, 130, 117  20 40 2.23 
anatabine 161  144, 117, 107 12 26 2.13 
d4-anatabine 167  148, 132, 111  20 20 2.13 
nornicotine 149  132, 117, 106  20 34 2.27 
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B.4. Identification criteria 
Identification criteria were defined according to the WADA Technical Document addressing 
qualitative assays, as described in the previous study (140). 
 
B.5. Method validation 
Calibration curves 
Similar to the previous study, a method validation approach was adopted considering guidelines 
on bioanalytical method validation from the US Food and Drug Administration (FDA) and the 
recommendations of the 3rd American Association of Pharmaceutical Scientists (AAPS)/FDA 
Bioanalytical Workshop in 2006 (141, 142). 
A pool of six urine samples from nicotine-abstinent individuals who had not been exposed to 
environmental smoke within the last 5 days was prepared to obtain negative urine (Uneg) for the 
validation process. 
Calibration was established over the 10-10’000 ng/mL range for nicotine, cotinine and trans-3-
hydroxycotinine and 10-5’000 ng/mL for nicotine-N’-oxide, cotinine-N-oxide, anabasine, anatabine 
and nornicotine. A set of three validation series was achieved, with calibration standards at six 
concentration levels (k = 6), with an additional point at ULOQ level after an 80-fold dilution, and 
validator standards (QC) at four concentration levels (k = 4), each being prepared in triplicate (n = 3). 
Calibration curves were built from the peak area ratio of nicotine to d4-nicotine, cotinine to d3-
cotinine, trans-3-hydroxycotinine, nicotine-N’-oxide and cotinine-N-oxide to d3-trans-3-
hydroxycotinine, nornicotine, anatabine and anabasine to d4-anabasine. Accuracy was defined as the 
closeness of agreement between the theoretical and the average measured concentrations. 
Precision expressed the closeness of agreement between a series of measurements obtained from 
multiple sampling of the same homogeneous sample under the prescribed conditions. Repeatability 
and intermediate precision are two of the three different levels of precision. Repeatability was 
defined as the RSD of the ratio of the intra-day standard deviation and the theoretical value at each 
concentration (143). Intermediate precision was expressed as the RSD of the ratio of the inter-day 
standard deviation on the theoretical value at each concentration. Accuracy profiles were built for 
each compound of interest, combining accuracy and intermediate fidelity variance in the dosing 
range (144, 145). 
The LLOQ and the ULOQ were determined as the lowest and the highest concentrations of QC 
samples with an acceptable accuracy, repeatability and intermediate precision. Quantitative analysis 
of target compounds in real urine specimens was performed using a three-points calibration curve 
determined and fitted by a linear least-squares regression of the peak area ratio of the analyte and 
 65 CHAPTER III | SMOKELESS TOBACCO IN SPORT 
 
the IS versus concentrations. The LOD was defined as the concentration that produced a Signal-to-
Noise ratio  3. 
 
Selectivity 
Selectivity assessment of interfering endogenous matrix compounds within selected tolerance 
windows was carried out by analyzing urine specimens certified as negative (< LOD) regarding 
nicotine and metabolites. For this purpose, a triplicate sample treatment of urine samples from 6 
nicotine-abstinent subjects who reported no exposure to environmental smoke within the last 5 days 
was conducted.  
Accordingly, influence of exogenous xenobiotics was considered when a substance appearing on 
the 2010 Prohibited List and Monitoring Program was highlighted by routine sample screening 
procedures. 
 
Carry-over 
Injection of a blank urine sample after analysis of the highest calibrator allowed assessing 
presence of target compounds due to carry-over effects. This experiment was conducted in triplicate. 
 
Matrix effects 
Evaluation of matrix effects on the ionization response and extraction efficiency was achieved in 
regards to recommendations published elsewhere (146). A neat solution was fortified at low, 
medium and high concentration in the initial mobile phase ACN: ammonium formate 10 mM (pH 3.0) 
buffer (99:1) (a), along with a pool of six urine samples from nicotine-abstinent subjects fortified in 
triplicate prior to sample treatment (b). By comparing the absolute peak areas of aqueous and urine 
solutions, matrix effect can be assessed, as reported below (Equation (1)). 
% Matrix effect (ME) = b/a (1) 
Adopting a DS approach, no extraction procedure was required, resulting in interchangeable 
process efficiency (PE) and matrix effect (ME). Indeed, with this particular sample treatment, ME may 
only be attributed to ionization of the analytes. 
 
Stability 
The effect of storage conditions was evaluated with stability assays designed to mimic the 
routine analytical throughput of samples. Analyte stability was studied by monitoring the influence of 
3 successive freeze and thaw cycles of QC urine samples (n = 3) at low and high concentrations within 
a week. Since real urine samples were stored at -20 °C in a dark room after collection, QCs were 
handled likewise and defrosted at ambient temperature 3 consecutive times within a week prior to 
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LC-MS/MS analysis. The initial integrated peak area was defined as 100%. Similarly, short-term 
temperature stability was assessed for QCs laying on the bench top at room temperature (21 °C) for 
24 h and in the autosampler at 10 ° C for 24h. 
 
C. Results and Discussion 
C.1. Method development 
 UHPLC-MS/MS analyses 
Compounds of interest, including nicotine and phase I metabolites along with minor tobacco 
alkaloids, were selected to highlight recent consumption of tobacco but also to gather 
comprehensive information on metabolism patterns to help distinguish between smoke and 
smokeless consumption in a future retrospective study. While phase II glucuronide conjugates of 
some metabolites may be excreted in abundance in urine, these compounds were not investigated. 
Indeed, the primary focus was on concentrations of nicotine with potential benefits on sport 
performance and relevant sensitivity was ensured for all phase I metabolites. Noteworthy, analysis of 
phase II glucuronide conjugates would require an additional hydrolysis step, which would not have 
completely allowed a sample treatment as straight-forward as the DS approach. Also, while an 
abundant literature on LC-MS/MS methods for the quantification of nicotine and selected 
metabolites in biological fluids has been published, only a handful of publications propose a simple 
and time-efficient sample treatment followed by fast analysis of a broad range of nicotine 
metabolites (105, 161, 162). 
Indeed, chromatographic and detection conditions were optimized to satisfy identification 
criteria while allowing a high analytical throughput as favored in dope testing. Accordingly, 
separation of nicotine, related metabolites and minor alkaloids in urine was found successful with 
HILIC, using a 50 mm column length and a gradient of ACN (A) and 10 mM ammonium formate (pH 
3.0) buffer (B) with a flow rate set at 800 L/min (Figure 17). Indeed, combining a high flow rate and 
a short HILIC column with adequate retention properties towards polar molecules and excellent peak 
shape offered a valuable association of short analysis time while maintaining good resolution. 
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Figure 17. UHPLC-MS/MS chromatogram of a urine specimen containing nicotine, nicotine metabolites and 
tobacco-related alkaloids at a concentration of 50 ng/mL, with IS spiked at 250 ng/mL for d4-nicotine and d4-
anatabine and 50 ng/mL for d3-cotinine and d3-trans-3-hydroxycotinine. 
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Interestingly, ionization of target compounds was optimized by use of a mobile phase highly 
enriched in polar organic solvent, which led to an increase of sensitivity (137). Also, coupling a TQ-MS 
analyzer to a UHPLC system brought a significant contribution to the enhancement of Signal-to-Noise 
ratio. Indeed, Multiple Reaction Monitoring (MRM) acquisition mode provided an efficient isolation 
of characteristic fragment ions for each molecule, resulting in reduced endogenous matrix 
interferences. Therefore, analytical conditions ensured the suitability of a DS sample treatment for 
urinary concentrations of nicotine, metabolites and minor alkaloids. 
Likewise, triple quadrupole MS/MS parameters were optimized by direct infusion of individual 
standard solutions. In consequence, compound specific normalized collision energy, cone voltage 
and dwell time were automatically tuned, producing a high sensitivity fragmentation pattern with a 
precursor ion response < 10% in abundance (Table 6). 
Eventually, repeatability of the retention times (tR) was assessed by calculating the RSD of each 
target compound over the set of three validation series, accounting for 21 urine specimens (Table 6). 
Actually, fluctuations in the chromatographic conditions, including freshly prepared mobile phases, 
may influence the variability of tR. Nevertheless, stability of tR was found satisfactory, as illustrated by 
a RSD ranging from 0.3 – 1.7% depending on the analyte. 
 
 Dilute-and-shoot sample treatment 
DS provided an interesting approach to the problem of finding a cost and time efficient sample 
treatment procedure when dealing with the consistent flow of urine specimens and restricted 
reporting time particular to dope testing (163-165). Indeed, this simple method involved only limited 
manipulation of sample, with feasibility for automation which proved efficient for performing large 
batches of analyses. Coupled with short chromatographic run times allowed by UHPLC, a significant 
workflow of analysis was achieved. Noteworthy, this method is accepted by WADA, as mentioned in 
the ISL (6).  
Since DS sample treatment is non-selective, as opposed to solid-phase (SPE) or LLE extraction, a 
variety of matrix compounds may compete with target analytes for ionization and account for 
substantial ME. Optimization of the dilution factor was carried out to reduce this phenomenon while 
maintaining sufficient sensitivity. In consequence, a 40-fold dilution appeared to provide an 
adequate compromise between these two parameters within the dynamic range of the mass 
analyzer. Also, dilution in ACN allowed improving urine clean-up due to protein precipitation and 
subsequent centrifugation, proving efficient to diminish potential ME. Therefore, chromatographic 
column lifetime could be extended and maintenance rate decreased compared to reversed phase 
chromatography where water is generally used for DS sample treatment.  
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Eventually, DS sample treatment provided a green alternative to SPE and LLE by requiring a low 
volume of organic solvent and avoiding addition of chemicals. Regarding the need of a mobile phase 
highly enriched in ACN for HILIC mode, this parameter was particularly valuable. 
 
C.2. Assay validation 
 Calibration curves 
Considering the pharmacological properties of nicotine and a doping perspective, concentration 
ranges were determined to comprehend urinary levels relevant for assessing recent consumption 
(147, 148). Accordingly, great efforts to develop an extensive clean-up procedure of urine samples 
could be avoided as quantification down to trace levels corresponding to environmental tobacco 
exposure or end of excretion phase after active consumption was unnecessary. Noteworthy, a fit-for-
purpose approach was adopted to determine the dilution factor, which could be lowered to achieve 
higher sensitivity and address the later problem. 
Calibration curves were built with calibration standards at six concentration levels, while 
evaluating different curves fitting. Referring to the accuracy profiles established over the dosage 
range, linear least-squares regression with 1/x2 weighting was chosen for quantification purpose, 
with R2 greater than 0.995 (Figure 18). 
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Figure 18. Absolute accuracy profiles for nicotine, nicotine metabolites and tobacco-related alkaloids. The solid 
line indicates the accuracy and the dashed lines represent the accuracy calculated as confidence interval (145). 
The dotted lines depict the acceptance limits of ± 30 %. 
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Repeatability and intermediate precision met the guidelines for bioanalytical method validation 
over the whole assay range, with RSD values lower than 15% (Table 7). Also, accuracy was found 
acceptable for all compounds of interest, with measured concentrations within ± 15% of every 
theoretical concentration. Noteworthy, an 80-fold dilution proved valid for concentrations exceeding 
the ULOQ. 
Table 7. Assay validation parameters for nicotine and metabolites (n = 3). 
 
Molecule 
Concentration 
(ng/mL) 
Accuracy 
(%CV) 
Precision 
Repeatability 
(%CV) 
Intermediate 
precision (%CV) 
nicotine 20 103.7 6.2 6.7 
 
500 101.1 6.3 8.3 
 
4’000 102.5 3.8 5.4 
 
8’000 99.3 3.1 3.8 
  
   
cotinine 20 101.9 5.5 5.9 
 
500 101.6 7.5 8.8 
 
4’000 100.4 2.9 4.7 
 
8’000 99.1 3.0 3.5 
  
   
trans-3-hydroxycotinine 20 95.9 5.0 5.0 
 
500 100.8 7.0 9.3 
 
4’000 102.1 4.8 7.0 
 
8’000 103.4 3.9 5.9 
  
   
nicotine-N’-oxide 20 77.7 3.1 4.0 
 
500 103.6 6.2 6.2 
 
2’000 107.5 2.4 2.4 
 
4’000 93.2 3.2 3.2 
  
   
cotinine-N-oxide 20 99.9 6.5 6.8 
 
500 104.5 6.8 9.1 
 
2’000 108.1 2.3 6.2 
 
4’000 95.8 3.9 5.1 
  
   
anabasine 20 105.5 4.0 4.1 
 500 103.8 7.4 9.8 
 2’000 104.3 4.8 5.1 
 4’000 96.8 2.9 3.6 
     
anatabine 20 104.1 8.1 9.9 
 500 97.0 7.5 8.2 
 2’000 105.7 4.3 5.5 
 4’000 104.0 3.7 5.2 
     
nornicotine 20 97.4 5.2 6.4 
 500 104.2 7.6 10.2 
 2’000 106.7 4.3 5.2 
 4’000 97.8 3.1 4.1 
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Therefore, direct quantification of target analytes in urine with this UHPLC-MS/MS method was 
suitable over the assay range. 
Eventually, a LOD standing around 1 ng/mL for all compounds could be estimated. 
 
 Selectivity 
Selectivity evaluation towards interfering endogenous matrix compounds was conducted on 6 
different urine specimens from nicotine-abstinent individuals who had not been exposed to 
environmental smoke within the last 5 days. According to triplicate sample treatment followed by 
UHPLC-MS/MS analysis, no interfering endogenous molecules were highlighted within selected 
transition windows as ion identification criteria were not met (140). Indeed, retention times, ion 
transitions and ion ratios parameters observed for matrix components significantly differed from 
each compound of interest.  
 Likewise, potential influence of exogenous xenobiotics was assessed relying on routine 
screening analysis of every urine specimen, searching for over 200 substances appearing on the 2010 
Prohibited List and Monitoring Program, followed by sample treatment and UHPLC-MS/MS analysis. 
Noteworthy, presence of stimulants commonly found in sport and society was investigated, including 
caffeine and pseudoephedrine. Accordingly, no exogenous xenobiotic highlighted by the screening 
procedure interfered with target analytes within selected transition windows, referring to the criteria 
mentioned earlier. 
 
Carry-over 
Carry-over was assessed by injecting a blank urine sample following the analysis of the highest 
calibrator for each compound of interest. This experiment was repeated three successive times. 
Presence of target analytes was not detected, confirming potential carry-over effects as a negligible 
phenomenon. 
 
Matrix effect 
Comparison of signals detected in urine and in the neat solution highlighted concentration-
dependant ion enhancement or suppression effects depending on the compound of interest. Indeed, 
evaluation of ME indicated ion suppression occurring at low level in the 70 to 98% range due to 
endogenous matrix compounds competing with target analytes towards ionization. Despite this 
phenomenon could be expected from a DS approach, the sample treatment method proved fit-for-
purpose, as illustrated by the good repeatability of these measurements (RSD < 15%) and the 
sufficient sensitivity to quantify all substances at the LLOQ. Likewise, all compounds showed 
substantial ion enhancement at medium and high concentrations, ranging from 104 to 124% and 107 
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to 125%, respectively, with evidence of good repeatability (RSD < 15%). Noteworthy, ME was 
efficiently corrected by the deuterated standards at all concentration levels. Therefore, influence of 
ME on the quantitative analyses was found negligible. 
 
 Stability 
Analyte stability was evaluated after investigation on the influence of the routine analytical 
throughput on compounds of interest in QC samples (n = 3) at low and high concentrations. Since 
stability experiments were designed to mimic actual storage and analysis conditions, QCs were 
preserved at -20 °C in a complete dark environment followed by a series of 3 successive freeze and 
thaw cycles within a week. Likewise, QC samples were left on the bench top at room temperature 
(21 °C) for 24 h and in the autosampler at 10 ° C for 24h to assess short-term temperature stability. 
According to minimal variations observed in the peak areas for analyte stability and short-term 
temperature stability assessments (RSD < 15%), storage conditions adopted during this study were 
adequate to ensure a high stability of all compounds of interest.  
 
D. Application to doping controls in 2010-2011 
Over a one-year period of time covering 2010 and 2011, every single urine specimen from 
regular doping controls of 43 different disciplines analyzed by LAD was included in this monitoring (n 
= 2’185). Referring to the 2009 ISL, article 19 of the World Anti-Doping Code and articles 24-27 of the 
UNESCO Convention against doping in sport, complete removal of identification means and a 
minimum storage period of three months were ensured prior to initiation of this research (3, 6, 149). 
Also, approval was received from ADCH to conduct this study. 
Due to the linear response observed after 1/x2 weighting in the assay validation, quantification 
was performed using calibration standards reduced to LLOQ, medium and ULOQ concentration levels 
(k = 3) and QCs to low and high concentration levels (k = 2), prepared each in triplicate. Also, a 
qualitative designation was assigned to compounds of interest detected in the LOD to LLOQ 
concentration range, namely traces. 
According to the quantitative assays, concentrations distribution of major nicotine metabolites, 
minor nicotine metabolites and tobacco alkaloids were found to range from LLOQ to 32’223, 6’670 
and 538 ng/mL, respectively (Figure 19). 
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Figure 19. Concentrations distribution for nicotine, its metabolites, minor tobacco alkaloids and tobacco-
related alkaloids. The solid red line indicates the cumulative percentage. 
 
Traces of major nicotine metabolites, minor nicotine metabolites and minor tobacco-related 
alkaloids accounted for 17.9 to 20.5%, 16.5 to 17.9% and 6.1 to 16.2% of urine specimens, 
respectively (Table 8). 
 
Analyte 
Concentration range 
x  LOD x  LLOQ Active exposure 
nicotine 17.9% 12.5% 9.3% 
cotinine 18.0% 16.1% 13.6% 
trans-3-hydroxycotinine 20.5% 18.1% 15.3% 
Cumulative exposure 23.0% 18.3% 15.3% 
    nicotine-N'-oxide 17.9% 11.9% 10.0% 
cotinine-N-oxide 16.5% 13.4% 11.4% 
anabasine 6.1% 2.8% 1.5% 
anatabine 8.2% 2.2% 1.1% 
nornicotine 16.2% 6.9% 4.2% 
 
Table 8. Prevalence of urine samples exposed to nicotine, major nicotine metabolites or minor tobacco 
alkaloids depending on the concentration range (n = 2’185). 
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Actually, at least one of the five different metabolites and three related tobacco alkaloids was 
detected in 23% of samples. Thus, exposure to nicotine, either due to active consumption or 
environmental tobacco smoke, concerned approximately twenty-three athletes out of a hundred. 
Considering a worldwide smoking prevalence of approximately 25%, as reported by the WHO, and 
huge progress towards implementation of a smoke-free environment, such findings support the 
potential use of nicotine in sport with a specific purpose (68, 166). When focusing on sports with a 
significant number of samples submitted to dope testing, cumulative exposure to nicotine 
metabolites and tobacco alkaloids was found to range between 26 and 56% of urine specimens for 
ice hockey, skiing, biathlon, bobsleigh, skating, football, basketball, volleyball, rugby, American 
football, wrestling and gymnastics (Table 9). 
 
 
Discipline n Active exposure 
Winter sports 
snowboarding 16 43.8% 
ski jumping 10 40.0% 
alpine skiing 38 36.8% 
ice hockey 96 36.5% 
bobsleigh 78 30.8% 
cross country skiing 34 23.5% 
biathlon 38 18.4% 
figure skating 41 17.1% 
Ball games 
beach volley 7 57.1% 
American football 19 55.6% 
floorball 54 38.9% 
rugby 25 28.0% 
basketball 24 20.8% 
football 201 19.4% 
handball 44 15.9% 
volleyball 35 14.3% 
tennis 31 12.9% 
Individual sports 
gymnastics 16 37.5% 
wrestling 31 32.3% 
artistic gymnastics 27 25.9% 
athletics 461 8.7% 
boxing 12 8.3% 
Endurance sports 
track cycling 15 20.0% 
road cycling 131 12.2% 
mountain bike cycling 18 5.6% 
rowing 21 4.8% 
triathlon 35 2.9% 
swimming 53 1.9% 
 
Table 9. Prevalence of active nicotine exposure in selected sports depending on the type of discipline. 
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Likewise, above-LLOQ levels of major nicotine metabolites, minor nicotine metabolites and 
minor tobacco-related alkaloids were quantified in 12 to 18%, 12 to 13% and 2 to 7% of urine 
specimens, respectively. At least one of the five different metabolites and three related tobacco 
alkaloids was measured in this concentration range in 18% of samples. As such, approximately 
eighteen athletes out of a hundred were exposed to smoke or ST or ETS within the last 3 days before 
doping control (135). Regarding the specific disciplines mentioned previously, recent cumulative 
exposure concerned 20 to 56% of urine specimens. 
Eventually, measuring prevalence of nicotine consumption prior to and/or during sport practice 
was carried out by hypothesizing conservative concentration limits for active exposure (50 ng/mL for 
nicotine, cotinine and trans-3-hydroxycotinine and 25 ng/mL for nicotine-N’-oxide and cotinine-N-
oxide), as previously depicted (135, 151). Likewise, since extensive exposure to second-hand smoke 
shortly before sport practice was extremely unlikely, contribution of ETS to such levels of 
concentration could be excluded. Thus, referring to those concentration ranges and considering 
major nicotine metabolites, minor nicotine metabolites and minor tobacco-related alkaloids, 
consumption of nicotine associated to sport training or competition was highlighted in 9 to 15% and 
10 to 11% of urine specimens, respectively. Noteworthy, at least one of these compounds of interest 
was present in such concentrations in 15% of samples. Accordingly, about fifteen athletes out of a 
hundred were considered as active nicotine consumers in competition, regardless of the sport 
discipline. These figures should be carefully interpreted as the statistical significance is not ensured 
for sports disciplines with low numbers of samples and as they correspond to the geographical area 
of Switzerland only. As a consequence, the true prevalence may be either underestimated or 
overestimated. However, while such statistics may appear lower than smoking prevalence in society, 
putting emphasis on winter sports, as well as a couple ball sports and individual sports, indicated a 
consumption prevalence comparable, if not far superior, to regular recreational use. Indeed, active 
exposure close to or during games and races has been highlighted in up to 57% of urine specimens, 
depending on the sport. 
Whether this significant prevalence is the consequence of a social trend within particular 
communities of athletes and/or an attempt to increase performances in specific disciplines remains 
unknown. Nevertheless, with respect to the detrimental effects of smoking on the respiratory 
system, these figures bring a significant support to the hypothesis of ST use, whether the primary 
purpose is performance enhancement or not (154-157). At present, a more definite number for 
prevalence of ST use could not be determined as there is no reported clinical study proposing a 
metabolic-based approach to distinguish between different forms of nicotine consumption. 
Nevertheless, a retrospective study after future development of biostatistical tools appears feasible 
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as a large number of compounds related to the metabolism of nicotine or tobacco alkaloids have 
been quantified. 
 
E. Conclusion 
This one-year monitoring study confirmed the alarming IC exposure levels previously described 
for ice hockey and highlighted a similar situation in several other sport disciplines. Due to the 
significance of the phenomenon, including nicotine to the Monitoring Program would allow 
determining geographical variations and assessing whether nicotine consumption is growing and 
durable or, on the contrary, stagnant, if not decreasing, and ephemeral. 
Considering a public health perspective, a preventive rather than repressive attitude in anti-
doping may be an interesting and innovative approach to tackle this alarming phenomenon. Indeed, 
while the inclusion of nicotine to the Prohibited List may reduce consumption of this molecule as a 
performance enhancer, actions and policies should primarily be elaborated in order to prevent the 
initiation and development of drug addiction during sport practice and its pursuit after a professional 
career. This holds particularly true as young generations of athletes tend to follow the steps of their 
older peers. While the frontier between recreational consumption and use for doping purpose is 
difficult to ascertain with social drugs, including caffeine or tetrahydrocannabinol (THC), toxicity of 
tobacco products is responsible for disastrous health effects greatly amplified by persistent addiction 
issues. 
Therefore, WADA and sport federations should evaluate the inclusion of nicotine to the 
Prohibited List and/or Monitoring Program in order to bring not only control on a potential doping 
agent, but also an innovative and key element to developing a more preventive approach of fight 
against doping. Indeed, an interesting step towards limitation and education on a global public 
health threat responsible for an extremely harmful burden of disease could be initiated within the 
sports community. 
This study was one of the key arguments to include nicotine to the Monitoring Program in 2012. 
 
III.3.3. Distinction between smoke and smokeless tobacco consumption 
A. Introduction 
According to the previous researches, there was a need for developing bioanalytical, statistical 
and probabilistic tools to distinguish between smoke and ST consumption, whether for identification 
of users or for specific prevalence measurements. Therefore, a clinical study on the metabolism of 
nicotine, tobacco-specific nitrosamines and tobacco combustion products was designed to answer 
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these questions (protocol in Appendix V.3). Approval was received by the Human Research Ethics 
Committee of Vaud to conduct this study. 
The project was conducted in collaboration with the Polyclinique Médicale Universitaire (PMU) 
and the Centre de Recherche Clinique (CRC) for medical supervision and assistance in the collection 
of biological samples, as well as the Institut de Santé au Travail (IST) for smoking in a controlled air-
flow exposure room. 
 
B. General plan 
In a first step, healthy male volunteers (n = 21) aged 20 to 30 years old who are occasional 
smokers were recruited by advertisement made at CHUV, the University of Lausanne (UNIL) and the 
Ecole Polytechnique Fédérale de Lausanne (EPFL). 
A preliminary briefing given by the investigator (François Marclay) covering the different aspects 
of the study was held for the volunteers who indicated their willingness to participate in this clinical 
study. An information sheet was given to the subjects as well as a consent form. In order to allow a 
sufficient reflection time, volunteers were asked to return this document within 3 days following the 
briefing. As soon as the consent was returned duly signed, volunteers were invited to the inclusion 
visit and underwent a medical examination conducted by a doctor of the PMU. Inclusion and 
exclusion criteria were checked using a questionnaire and a subject number was randomly assigned 
to each participant (details in Appendix V.3). This number was reported in the case observation form 
and only the investigator and his staff, all subject to professional secrecy, had access to the personal 
data of the volunteers. 
The protocol to monitor the metabolism of nicotine, tobacco-specific nitrosamines and tobacco 
combustion products is summarized in Table 10. 
Phase 1 2
Day 1 2 3 1 2 3
Blood & urine
sample collection
Cigarette
Snus
t0 t1 t2 t3 t6t5 t7*
* = urine sample only
t4
t1 t2 t3 t6t5 t7*t4t0
Consumption
Consumption
 
Table 10. Exposure to nicotine and sample collection protocol for the clinical study. 
 
In order to guarantee the absence of tobacco-related compounds in the body, the participants 
were asked not to consume nicotine during the 3 days prior to and after the start of each phase of 
the study. 
On day 1 of the first phase, a standard cigarette (Parisienne Jaune) of 0.8 g tobacco containing 
0.7 mg of nicotine was smoked by the volunteers in a controlled environment at the IST. A MoNIC 
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(Moniteur de NICotine) badge had also been pinned to each participant’s garment in order to 
measure the extent of self-induced second-hand exposure during this phase (167). Blood samples 
were collected at t0 = 0h (before exposure), t1 = 2h, t2 = 4h, t3 = 6h, t4 = 8h, t5 = 10h and t6 = 24h after 
intake. Similarly, urine samples were collected at t0 to t6 and t7 = 48h after consumption. Then, a 
week break was observed to ensure complete removal of substances of interest from the body. 
On day 1 of the second phase, a 24 g bag of snus tobacco containing 8mg of nicotine was used 
by the volunteers for a period of 30min at the CRC. The blood and urine samples were collected 
similarly to the first phase. 
In practice, blood samples (minimum 5mL of serum) were collected in duplicates directly by the 
CRC medical staff from t0 to t6. One of each duo of samples was successively centrifuged, aliquoted 
and frozen at -20 °C until being analyzed while blood parameters of the other one were determined 
using a Sysmex blood analyzer before centrifugation and freezing. Urine samples (minimum 50mL) 
were collected by the volunteers in containers provided for this purpose from t0 to t7. In order to 
normalize the concentrations of the compounds of interest, creatinine was measured using a clinical 
chemistry rapid assay and urine specific gravity using a refractometer. The pH was also calculated 
alongside. Afterwards, the urine samples were aliquoted and frozen at -20 °C until analysis. 
This project having not been completed yet, the key linking the random subject number to the 
participant will be destroyed at the end of the study to ensure complete and definitive 
anonymisation of the samples. 
 
C. Bioanalytical strategy 
This project was subdivided into several sub-sections to prioritize the parts offering a good 
balance between promising value for discrimination and compatibility with routine doping analyses 
(Table 11). 
 
Analyte Matrix 
Discrimination 
potential 
Doping analyses 
compatibility 
Priority 
nicotine and metabolites 
urine medium high 1 
blood medium high 2 
     
tobacco combustion products 
urine high low 3 
blood high low 4 
     
tobacco-specific nitrosamines 
urine low medium 5 
blood low medium 6 
 
Table 11. Summary of the different analytical parts of the clinical study on smoke and smokeless consumption. 
An order of priority has been established for each part depending on the compatibility with routine analytical 
doping tests and the discrimination potential between each population of user. 
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As an end goal to this clinical study, the discrimination potential through the identification of 
biomarkers for distinguishing between smoke and ST consumption was naturally of outmost 
importance. Since one form implies tobacco pyrolysis, as opposed to the other one, combustion 
products (hydroxynapthol, hydroxypyrene and hydroxyfluorene and related glucuronides) were very 
likely to be found in significantly larger quantities. Therefore, the hypothesis upon which these 
molecules offered the highest potential was relatively self-explanatory and related to the very 
distinct physical natures of each form of use. As absorption routes differ for both forms of 
consumption, differences in the pharmacokinetic of nicotine metabolism (nicotine, cotinine, trans-3-
hydroxycotinine, nicotine-N’-oxide, cotinine-N-oxide and related glucuronides) and minor tobacco 
alkaloids (anabasine, anatabine and nornicotine) could be reasonably hypothesized. Eventually, the 
curing process of smoke and ST being different, variations in the quantity of tobacco-specific 
nitrosamines (in particular 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and glucuronide) 
absorbed could be expected. Nevertheless, due to the large intra-variability within batches of 
production and inter-variability between brands reported in the literature, these molecules were 
attributed the lowest potential for discrimination. 
A higher priority was given to analytes which would require a sample preparation and 
instrumentation fitting with routine doping analyses. The possibility to include biomarkers for the 
distinction between smoke and ST consumption to existing urine or blood analyses run on a weekly 
basis was considered a huge asset. Since anti-doping requires cost- and time-efficient procedures, 
there is a constant push towards the synergy of different methods for the rapid analysis of large 
numbers of molecules. According to the literature, the most recent approaches for nicotine and 
metabolites analysis employ DS or mixed-mode cation exchange SPE (MCX) sample preparations, 
whether with or without an hydrolysis step for the deconjugation of glucuronated metabolites, 
before injection on a UHPLC-MS/MS system. These techniques being widely used in routine anti-
doping analyses, nicotine and metabolites were considered most compatible compared to the other 
molecules of interest. The analysis of tobacco-specific nitrosamines implies similar methods but the 
demand for a higher sensitivity due to lower concentrations in blood and urine and the need for a 
hydrolysis step during sample preparation made these compounds slightly less compatible with 
routine doping analyses. Eventually, tobacco combustion products require a more challenging and 
extensive sample preparation due to their extremely low abundance in biological samples. 
Accordingly, a dedicated analytical procedure is needed. Also, as combustion products are not 
tobacco-specific, the analysis of nicotine and metabolites is a prerequisite to screen for tobacco 
users. Therefore, these molecules were considered as the least compatible with the routine 
laboratory workflow. 
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WADA pressed the argument that the issue of distinguishing between different origins of a 
substance with a prohibited and a non-prohibited status is a key objective. In accordance with the 
Code, priority should be given as much as possible to finding specific markers of the prohibited route 
of administration to unambiguously demonstrate the origin of the product. In these views, WADA 
stated that even if the objectives of this study were well identified, the order of priority did not 
appear in line with an optimized and practical outcome in the anti-doping field. From a fundamental 
science perspective, the author agrees with the philosophy described by WADA. Nevertheless, since 
anti-doping is practical science by nature, method developments should be compatible with routine 
analysis requirements or, at least, offer a reasonable two-steps solution comprising routine and 
confirmation analyses. Considering the bioanalytical challenges discussed in this section, routinely 
screening for combustion products is unimaginable, thus making it a confirmatory analysis. As a 
matter of balance, and to use the words of WADA, giving priority to nicotine and metabolites was 
found to be more in line with an optimized and practical outcome in the anti-doping field due to the 
theoretical possibility of integration to routine protocols and the potential discriminating power. 
In summary, priority was given to the analysis of nicotine and metabolites, followed by 
combustion products and tobacco-specific nitrosamines. 
Eventually, urine is still the primary matrix used in dope testing and came first in order of 
priority compared to blood even though the latter is more informative in terms of pharmacokinetics. 
 
D. Part I: Nicotine and metabolites in urine 
D.1. Experimental 
The previous analytical method for the simultaneous determination and quantification of 
nicotine, its four main unconjugated metabolites and minor tobacco alkaloids in urine involved DS 
sample treatment followed by UHPLC-TQ-MS/MS analysis in HILIC mode. 
For the present study, the 10 ng/mL LLOQ for the compounds of interest offered by this 
approach was found to be a limitation as concentration levels reached after the consumption of a 
single cigarette or snus pouch were expected to be in the low range. While this analytical method 
would be satisfactory for measuring peak concentrations, samples shortly after nicotine consumption 
or towards excretion completion might have been problematic. Therefore, as superior sensitivity and 
selectivity were required, a MCX sample preparation was developed to replace the DS procedure. 
Nevertheless, the LLOQ reported in the literature for the glucuronated metabolites of nicotine, 
cotinine and trans-3-hydroxicotinine would not have been fit-for-purpose (162, 168). In particular, 
the measurement of cotinine-glucuronide may have been an issue. As a consequence, a hydrolysis 
step was introduced prior to MCX extraction to recover both free and conjugated metabolites (total 
fraction) under their free form, while a second aliquot of the same sample was directed extracted by 
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MCX to obtain the free metabolites alone (free fraction). A simple subtraction between the total and 
the free fractions allowed obtaining the concentrations of the glucuronated metabolites. A 
pentafluorophenylpropyl (F5) stationary phase was also chosen in order to increase the selectivity 
between nicotine and anabasine as these molecules have the same molecular weight and very close 
chromatographic behaviors in HILIC mode. 
 
Sample preparation 
An aliquot of urine (2 mL) was spiked with 40 L of deuterated internal standard (IS) solution 
(d4-nicotine, d3-cotinine, d3-trans-3-hydroxycotinine and d4-anatabine at 2.5 g/mL in MeOH) and 
split in two fractions of equal volume. 1mL of 0.2M phosphate buffer (pH 6.7) and 50 l of β-
glucuronidase were added to the first aliquot prior to incubation at 50 °C overnight in a 
thermostated water bath. Afterwards, both fractions were acidified with 1 mL of 2% aqueous formic 
acid to adjust the pH to ~2.5. After vortex mixing, the aliquots were centrifuged for 5 min at 2500 
rpm and subjected to SPE. Briefly, Oasis MCX cartridges (3cm3, 60mg, Waters, Milford, USA) were 
conditioned with 1 mL of MeOH followed by 1 mL of 2% aqueous formic acid. The samples were 
loaded onto the cartridges prior to a washing step with 1 mL of 2% aqueous formic acid and 250 L 
of MeOH. Analytes were eluted with 1 mL of 5% (v/v) ammoniated MeOH. 100 L of 1% HCl in MeOH 
were added in order to improve nicotine recovery. After vortex mixing, the samples were evaporated 
to dryness under a gentle air stream at 40 °C and reconstituted in 150 L of 10 mM ammonium 
acetate (pH 5.0): MeOH (70:30, v/v) prior to UHPLC-TQ-MS/MS injection. 
 
Efficiency of -glucuronidase hydrolysis 
Aliquots of urine (1 mL) were spiked with 20 L of deuterated internal standard IS solution and 
20 L of a standard solution containing glucuroconjugated compounds (nicotine-N--glucuronide, 
cotinine-N--D-glucuronide and trans-3-hydroxycotinine-O--D-glucuronide at 10 g/mL in MeOH). 
1mL of 0.2M phosphate buffer (pH 6.7) and 50 l of β-glucuronidase were added prior to incubation 
at 37 °C for different times (2, 4, 6, 8, 10 and overnight) in a thermostated water bath. Afterwards, 
the samples were acidified with 1 mL of 2% aqueous formic acid to stop the hydrolysis and adjust the 
pH to ~2.5 prior to SPE extraction and UHPLC-TQ-MS/MS analysis. Each sample was prepared in 
triplicate. 
 
UHPLC conditions 
Separation was carried out on an Acquity UPLC System (Waters, Milford, USA) with a Supelco 
Ascentis Express F5 column (2.1 x 100 mm, 2.7 m, Sigma-Aldrich, Buchs, Switzerland). Column and 
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autosampler tray temperatures were set at 30 °C and 10 °C, respectively. Mobile phase consisted of 
10 mM ammonium acetate (pH 5.0) buffer (A) and MeOH with 0.001% formic acid (B) with a flow 
rate set at 250 L/min. Initial mobile phase was 65% A decreased linearly to 50% over 4.5 min and 
then to 30% at 4.51 min. The column was washed during 0.3 min and mobile phase increased back to 
65% to re-equilibrate the system for 0.7 min. The total run time was 5.5 min. Injection volume was 
fixed at 10 L in full loop mode. 
 
Triple Quadrupole-MS parameters 
Analyses were performed using a Waters Xevo™ TQ-S triple quadrupole mass spectrometer 
equipped with an ESI source operating in positive mode. MS operating conditions were set as 
follows: desolvation gas flow set at 600 L/h at a temperature of 550 °C, capillary voltage at 3.0 kV in 
positive mode, cone voltage and collision energies optimized for each compound (Table 12). The 
source temperature was 150 °C, the cone gas flow was set to 150 L/h and the collision gas flow was 
0.15 mL/min. 
*Quantification ion transitions are in bold. 
Table 12. MRM parameters and retention times of the analytes. 
 
Identification criteria 
Identification criteria were defined according to the WADA Technical Document addressing 
qualitative assays, as described in the one-year monitoring study (140). 
 
 
 
Molecule MRM transition (m/z)* 
Collision 
energy (eV) 
Cone 
voltage (V) 
tR (min) 
nicotine 163  132, 117, 84 15 18 2.27 
d4-nicotine 167  136, 134, 121 20 20 2.28 
cotinine 177  146, 98, 80 16 20 2.04 
d3-cotinine 180  146, 101, 81 20 20 2.04 
trans-3-hydroxycotinine 193  134, 86, 80 20 16 1.36 
d3-trans-3-hydroxycotinine 196  134, 89, 80 20 20 1.36 
nicotine-N’-oxide 179  132, 130, 117 18 20 2.29 
cotinine-N-oxide 193  134, 96, 79 18 14 1.16 
anabasine 163  146, 130, 117 20 40 2.76 
anatabine 161  144, 117, 107 18 26 2.36 
d4-anatabine 167  148, 132, 111 20 20 2.35 
nornicotine 149  132, 117, 106 20 34 1.95 
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Method validation 
Calibration curves 
The method validation approach was a replica of the one-year monitoring study, let aside the 
calibration which was established over the 1-500 ng/mL concentration range, or on a more limited 
range depending on the analytes. Noteworthy, as the hydrolysis step was avoided for the calibrator 
standards, the volumes were divided by two, corresponding to 1 mL of urine and 20 L of IS. 
Alternatively, the validator standards underwent the complete MCX sample preparation described 
previously to assess the influence of this hydrolysis process. 
 
Selectivity 
Selectivity assessment of interfering endogenous matrix compounds within selected tolerance 
windows was carried out as a replica of the approach adopted in the one-year monitoring study. 
 
Carry-over 
Likewise, carry-over experiments were conducted as in the one-year monitoring study. 
 
Matrix effects 
Evaluation of matrix effects on the ionization response and extraction efficiency was achieved 
similarly to the study on nicotine consumption during the 2009 IIHF World Championships.  
 
Stability 
Again, the effect of storage conditions was evaluated as in the one-year monitoring study. 
 
D.2. Results and Discussion 
Method development 
 UHPLC-MS/MS analyses 
Target compounds, including nicotine, metabolites and related glucuronides along with minor 
tobacco alkaloids, were selected to gather a wide spectrum of information on metabolism patterns 
after smoke and ST consumption. With pharmacokinetics as a primary focus, phase II glucuronide 
conjugates were also investigated as some metabolites constitute a significant part of the total 
urinary excretion. In order to ensure fit-for-purpose sensitivity in the measurement of the 
glucuronated compounds, each sample was split in two fractions to be analyzed after MCX sample 
treatment or hydrolysis followed by MCX sample treatment. While not as straight-forward and cheap 
as DS, this approach offers efficient sample clean-up, which is particularly important for 
quantification purposes. 
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As described in the previous studies, chromatographic and detection conditions were optimized 
to satisfy identification criteria while allowing a high analytical throughput as favored in dope testing. 
Separation of nicotine, related phase I metabolites and minor alkaloids in urine was found successful 
with  the F5 stationary phase, using a 100 mm column length and a gradient of 10 mM ammonium 
acetate (pH 5.0) buffer (A) and MeOH with 0.001% formic acid (B) with a flow rate set at 250 L/min 
(Figure 20). Relying on a F5 column offered interesting retention properties towards polar molecules, 
allowing increasing the selectivity between nicotine and anabasine as compared to HILIC, while 
maintaining very good peak shape. The recent release of the Express line of columns dedicated to 
UHPLC, as opposed to the regular line of LC columns compatible with UHPLC systems, allowed a very 
significant reduction of the total analysis time compared to the literature (101, 162, 168). On a 
further note, the lower flow rate and avoiding the use of ACN as the primary solvent constituting the 
mobile phase was also a greener alternative to HILIC. 
 
 
Figure 20. UHPLC-MS/MS chromatogram of a urine specimen containing nicotine, nicotine metabolites and 
tobacco-related alkaloids at a concentration of 25 ng/mL, with IS spiked at 50 ng/mL for d4-nicotine, d3-
cotinine, d3-trans-3-hydroxycotinine and d4-anatabine. 
 
Triple quadrupole MS/MS parameters were optimized in the previous study to obtain 
compound specific normalized collision energy, cone voltage and dwell time and produce a high 
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sensitivity fragmentation pattern. Since the same instrument was used for this research, the MS/MS 
parameters were retrieved from the previous study (Table 12). 
Eventually, repeatability of the retention times (tR) was assessed by calculating the RSD of each 
target compound over the set of three validation and calibration series, accounting for 27 urine 
specimens (Table 12). Even though fluctuations in the chromatographic conditions, including freshly 
prepared mobile phases, may influence the variability of tR, the stability was found satisfactory with a 
RSD ranging from 0.2 – 1.3% depending on the analyte. 
 
 MCX sample treatment 
MCX sample treatment was a very significant improvement in terms of sensitivity and selectivity 
compared to both DS and LLE. While not as cost and time efficient as DS sample treatment, the 
preparation of a set of 48 samples could be achieved within 3h, allowing dealing with the large 
volume of samples collected during the clinical study in a short period of time. 
Since the dilute-and-shoot sample treatment previously used was non-selective, SPE on MCX 
cartridges allowed filtering out most matrix compounds that may cause selectivity issues and 
compete with target analytes for ionization and/or result in substantial ME. Extracts were found to 
be very clean and the MCX procedure allowed a ~6.5-fold concentration of compounds of interest, 
which was an interesting gain in sensitivity compared to dilute-and-shoot. Also, chromatographic 
column lifetime was found to be notably extended and maintenance rate decreased with the 
improved urine clean-up, even without the use of a pre-column. 
RE of free metabolites ranged from 87.6 to 101.1% depending on the analyte, with evidence of 
good repeatability (RSD < 10%), and showed only slight dependency on the concentration level 
(Table 13). 
Table 13. Recovery and related RSD of nicotine, related metabolites and minor tobacco alkaloids at low, 
medium and high concentrations (n = 3). 
 
Molecule 
Concentration (ng/mL) Recovery (%) RSD (%) 
Low Medium High Low Medium High Low Medium High 
nicotine 1 250 500 97.8 96.4 97.2 5 2 4 
cotinine 1 250 500 99.1 98.7 101.1 4 3 3 
trans-3-hydroxycotinine 1 250 500 94.2 95.5 97.3 6 4 7 
nicotine-N’-oxide 2.5 50 100 90.6 91.1 92.9 4 7 2 
cotinine-N-oxide 2.5 50 100 87.6 89.5 90.2 8 4 3 
anabasine 1 100 250 99.2 100.8 101.1 3 4 7 
anatabine 1 250 500 96.7 95.3 97.4 6 5 2 
nornicotine 1 250 500 98.5 98.6 95.3 7 2 8 
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Also, as MCX is gaining popularity in dope testing, extraction of nicotine and metabolites could 
potentially be combined with other prohibited substances (169). According to the previous study and 
since the routine procedure at LAD relies on DS sample preparation, nicotine, major phase I 
metabolites and minor tobacco alkaloids can be included to the screening method. In a second step, 
these compounds and major phase II metabolites could be integrated to the MCX sample clean-up 
used at LAD for confirmatory analysis of basic and neutral compounds (169). Therefore, MCX should 
be regarded as a confirmatory method in the perspective of distinguishing forms of tobacco 
consumption. 
 
Efficiency of -glucuronidase hydrolysis 
As previously reported in the literature, the hydrolysis of the three glucuronides was >90% 
within the first 6h and complete overnight at 37°C as confirmed by UHPLC-TQ-MS/MS analysis (data 
not shown) (101). 
 
Assay validation 
 Calibration curves 
Considering the pharmacological properties of nicotine, concentration ranges were determined 
as a compromise between the urinary levels expected after consumption of a single dose of smoke or 
ST and the analytical capabilities. 
Calibration curves were built with calibration standards at five concentration levels, while 
evaluating different curves fitting. Referring to the accuracy profiles established over the dosage 
range, linear least-squares regression with 1/x2 weighting was chosen for quantification purpose, 
with coefficients of determination (R2) greater than 0.995 (Figure 21). 
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Figure 21. Absolute accuracy profiles for nicotine, nicotine metabolites and tobacco-related alkaloids. The solid 
line indicates the accuracy and the dashed lines represent the accuracy calculated as confidence interval (145). 
The dotted lines depict the acceptance limits of ± 30 %. 
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Repeatability and intermediate precision met the guidelines for bioanalytical method validation 
over the whole assay range, with RSD values lower than 10% (Table 14). Also, accuracy was found 
acceptable for all compounds of interest, with measured concentrations within ± 10% of every 
theoretical concentration. The criteria defined by the guidelines were also met for validator 
standards which underwent hydrolysis with RSD values lower than 15% for repeatability and 
intermediate precision, and with measured concentrations within ± 15% of every theoretical 
concentration (data not shown). Therefore, the influence of hydrolysis was found negligible. 
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Table 14. Assay validation parameters for nicotine and metabolites (n = 3). 
 
Therefore, direct quantification of target analytes in urine with this UHPLC-MS/MS method was 
suitable over the assay range (1-500 ng/mL for nicotine, cotinine, trans-3-hydroxycotinine, anatabine 
Molecule 
Concentration 
(ng/mL) 
Accuracy 
(%CV) 
Precision 
Repeatability 
(%CV) 
Intermediate 
precision (%CV) 
nicotine 1 100.0% 1.9% 2.1% 
 
5 96.2% 1.0% 1.2% 
 
25 96.2% 0.3% 0.3% 
 
100 100.3% 0.1% 0.1% 
 
500 101.9% 0.4% 0.4% 
  
   
cotinine 1 100.4% 6.6% 6.7% 
 
5 99.1% 1.8% 2.0% 
 
25 104.1% 1.0% 1.0% 
 
100 102.7% 0.7% 0.7% 
 
500 95.5% 3.6% 3.7% 
  
   
trans-3-hydroxycotinine 1 101.1% 7.1% 7.1% 
 
5 96.8% 1.3% 1.3% 
 
25 99.5% 3.2% 3.4% 
 
100 101.8% 0.2% 0.2% 
 
500 96.5% 0.1% 0.2% 
  
   
nicotine-N’-oxide 2.5 100.7% 2.6% 2.6% 
 
5 102.7% 1.1% 1.6% 
 
25 101.0% 5.3% 5.3% 
 
50 99.0% 5.2% 5.7% 
 
100 100.6% 3.7% 3.9% 
  
   
cotinine-N-oxide 2.5 98.1% 7.6% 7.2% 
 
5 102.8% 3.6% 4.0% 
 
25 104.1% 1.0% 1.4% 
 
50 95.3% 6.3% 6.1% 
 
100 92.4% 2.5% 2.4% 
  
   
anabasine 1 97.7% 3.6% 4.8% 
 5 105.6% 2.7% 2.7% 
 25 104.1% 1.1% 1.4% 
 50 98.5% 1.3% 1.7% 
 250 90.0% 1.1% 1.2% 
     
anatabine 1 94.2% 5.4% 5.8% 
 5 97.7% 1.5% 1.5% 
 25 105.9% 5.0% 4.8% 
 100 107.3% 2.1% 2.1% 
 500 98.2% 0.5% 0.5% 
     
nornicotine 1 97.9% 4.0% 3.7% 
 5 104.9% 1.5% 1.6% 
 25 102.2% 1.8% 2.0% 
 100 105.9% 0.7% 1.2% 
 500 98.7% 2.0% 1.9% 
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and nornicotine, 2.5-100 ng/mL for nicotine-N’-oxide and cotinine-N-oxide and 1-250 ng/mL for 
anabasine). 
Eventually, a LOD standing around 0.25 ng/mL could be estimated for nicotine, cotinine, trans-3-
hydroxycotinine, anabasine, anatabine and nornicotine, and  around 0.5 ng/mL for nicotine-N’-oxide 
and cotinine-N-oxide. 
 
Selectivity 
Selectivity evaluation towards interfering endogenous matrix compounds was conducted on 6 
different urine specimens from nicotine-abstinent individuals who had not been exposed to 
environmental smoke within the last 5 days. According to triplicate sample treatment followed by 
UHPLC-MS/MS analysis, no interfering endogenous molecules were highlighted within selected 
transition windows. Indeed, MCX provided very clean sample extracts.  
 Likewise, potential influence of exogenous xenobiotics was assessed relying on the analysis of 
all the clinical study samples at t0, accounting for 42 urine specimens. Noteworthy, presence of 
stimulants commonly found in sport and society was also investigated, in particular caffeine and 
pseudoephedrine. Accordingly, no exogenous xenobiotic was highlighted and interfered with target 
analytes within selected transition windows. 
 
Carry-over 
Assessment of carry-over was performed by injecting a blank urine sample following the analysis 
of the highest calibrator for each compound of interest. This experiment was repeated three 
successive times and no target analyte was detected, confirming the absence of carry-over effect. 
 
Matrix effect 
Comparison of signals detected in urine and in the neat solution highlighted concentration-
dependent ion enhancement or suppression effects depending on the compound of interest. Indeed, 
evaluation of ME indicated slight ion suppression or enhancement occurring at low, medium and 
high concentrations, ranging from 89 to 102%, 93 to 99% and 95 to 101%, due to endogenous matrix 
compounds competing with target analytes towards ionization (data not shown). According to the 
excellent repeatability of these measurements (RSD < 10%), the increased sensitivity and selectivity 
of the method to quantify all substances at LLOQ, the sample treatment method proved fit-for-
purpose. Noteworthy, ME was efficiently corrected by the deuterated standards at all concentration 
levels. Therefore, influence of ME on the quantitative analyses was found negligible. 
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 Stability 
Analyte stability was evaluated after investigation on the influence of the routine analytical 
throughput on compounds of interest in QC samples (n = 3) at low, medium and high concentrations. 
Since stability experiments were designed to mimic actual storage and analysis conditions, QCs were 
preserved at -20 °C in a complete dark environment followed by a series of 3 successive freeze and 
thaw cycles within a week, a fourth cycle after three months, a fifth after six months and a final one 
after one year to assess long-term stability. Likewise, QC samples were left on the bench top at room 
temperature (21 °C) for 24 h and in the autosampler at 10 ° C for 24h to assess short-term 
temperature stability. 
According to the minimal variations observed in the concentration measurements across the 
stability tests (RSD < 15%), storage conditions adopted during this study were adequate to ensure a 
high stability of all compounds of interest. 
 
E. Application to clinical study samples 
During the course of the clinical study, a total of 320 urine samples from 21 volunteers were 
collected. Out of this initial testing pool, urinary measurements from three subjects were excluded, 
either for canceling the scheduled ST consumption phase on their part or for exhibiting positive 
concentration values at t0 despite the 72h nicotine consumption abstinence period required prior to 
each phase of the study. Therefore, analytical results reported in this document correspond to a 
population of 18 volunteers, accounting for 288 urine samples. 
Sample preparation and quantification were performed according to the methodology described 
in the experimental and assay validation parts. Also, a quantitative value of 0 ng/mL was assigned to 
compounds of interest either detected in the LOD to LLOQ concentration range or not detected at 
all. 
Concentration values collected during the quantitative assays allowed building concentration 
profiles over time to depict the metabolism of nicotine, cotinine, trans-3-hydroxycotinine and their 
related glucuronides. Conversely, concentration distributions of minor nicotine metabolites and 
tobacco alkaloids could not be exploited due to trace levels being detected at best. Indeed, as the 
single dose of smoke or ST was not sufficient for measuring these compounds above the LLOQ at 
almost all collection times, concentration profiles could not be built for the population of volunteers. 
Comparing concentrations levels would be misleading as the nicotine dose administered to each 
volunteer was directly depending on the gesture for both forms of consumptions. In addition, MoNIC 
badges indicated that self-induced second-hand exposure to smoke, and thus to nicotine, varied 
from one volunteer to another despite exposure in a controlled environment with a high ventilation 
rate. Therefore, results should be interpreted with regards to the metabolism rate of each 
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metabolite or ratios between metabolites rather than concentration values. Reporting urinary 
biomarkers as normalized ratios to urinary creatinine concentrations to control for variations in urine 
flow rate did not affect the concentration patterns. As volunteers were encouraged to drink a lot of 
water on exposition days in order to keep hydrated and ease the blood and urine collection process, 
the influence of urine concentration was found negligible. Therefore, normalization with creatinine 
was not relevant in this study and raw data will be presented. On the whole, a very close fit was 
observed between the urinary profiles obtained after smoke and ST consumption (Figure 22).  
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Figure 22. Mean urinary concentration profiles of nicotine and related major phase I and II metabolites after 
smoke and ST consumption for the 18 volunteers. The vertical lines indicate the standard deviation at 95% 
confidence intervals. 
 
 No cross-over points were observed when comparing smoke and smokeless concentration 
profiles of all target compounds. Regardless of the product, the highest concentration was measured 
at t1 (2h) for nicotine and nicotine-glucuronide, t2 (4h) for cotinine, between t3 and t4 (6-8h) for 
cotinine-glucuronide, at t5 (10h) for trans-3-hydroxicotinine and at t3 (6h) for trans-3-
hydroxicotinine-glucuronide. Therefore, a slight delay was found for cotinine-glucuronide between 
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cigarette smoking and snus consumption as the highest point was reached at 6h and 8h, respectively. 
Likewise, while peak concentration of nicotine was reached after 2h for both forms of consumption, 
the decline of nicotine concentrations in urine appeared to occur at a slightly slower rate with ST 
(Figure 22 and 23, Table 14). 
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Figure 23. Urinary concentration profiles of nicotine after smoke or ST consumption for the 18 volunteers. The 
bold lines indicate the mean pharmacokinetic profiles for the entire population of subjects. 
 
Nevertheless, a statistical significance would be difficult to assume due to the limited 
intervariability between urinary profiles and as concentrations achieved within the 2h intervals prior 
and after each time point are unknown. Indeed, determining the exact time and true value of peak 
concentrations would require considerably shorter time intervals between urine collection points, 
which would be quite inconceivable from a practical point of view. Also, smokeless tobacco 
consumption showed a higher intra-variability of nicotine concentrations ranges at each time point 
compared to smoked tobacco (Table 14). A similar situation was observed for the other metabolites 
(data not shown). This further illustrates the difficulty to highlight a statistically significant difference 
between urinary profiles after each type of tobacco use. 
Table 14. Ranges of urinary concentrations for nicotine at the different time points depending on the type of 
product consumed by the 18 volunteers. 
 
These observations confirm data previously reported in the literature, indicating a slightly 
slower absorption rate through the buccal mucosa than the lungs, which may also affect the glucuro-
conjugation rate as a consequence (92). However, differences of such limited magnitude would not 
be sufficient factors for unequivocal distinction between smoke and ST use. With a single exposure 
to each form of tobacco consumption, metabolic intra-variability for each volunteer remains difficult 
to ascertain. Therefore, careful assumptions are made here when interpreting differences observed 
Product type  
Nicotine concentration (ng/mL) 
t0 t1 t2 t3 t4 t5 t6 t7 
smoke 
Range 0 23-176 0-58 6-37 0-31 0-18 0-29 0 
Mean 0 74 25 19 13 8 8 0 
smokeless 
Range 0 27-268 19-410 15-128 2-104 0-55 0-32 0 
Mean 0 118 102 45 31 19 9 0 
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in the fitting of the concentration profiles. From an anti-doping perspective, the situation is even 
more complicated and blurry as real life use of snus in sports such as ice hockey induces cumulative 
effects. Indeed, the community has reported the use of multiple pouches during the games, or at 
least regular daily use during training. In this context, complexity of the metabolic profiles would 
certainly be augmented. 
Likewise, combining pairs of compounds to build concentration profiles on the basis of 
metabolites ratios was not found to bring additional relevant information as this data processing 
tended to further reduce the intra- and inter-variability for the most part. Therefore, urinary profiles 
of nicotine and related major phase I and II metabolites after smoking or ST use were not found to 
bring relevant information in the perspective of distinguishing both forms of consumption. According 
to the literature, concentration in blood is thought to raise at a slower rate with smokeless tobacco, 
as compared to tobacco smoke (92). Therefore, measuring concentration profiles for blood 
specimens might be more promising. Similar results might be highlighted though and glucuro-
conjugated metabolites will be absent in blood. The additional analysis of combustion products 
seems to hold more potential. Nevertheless, considering the difficulties to measure minor nicotine 
metabolites and tobacco alkaloids, one may argue that investing efforts in achieving part 2 of the 
clinical study may not be worth it. Indeed, as pyrolysis products are found in low levels in regular 
cigarette smokers, the single dose administered in this study might result in undetectable trace 
amounts or low concentrations compatible with environmental exposure. Practically, the profiles 
indicate that analyzing for nicotine and major phase I and II metabolites in urine can be considered as 
a screening procedure only. DS routine analyses should integrate nicotine and major phase I 
metabolites to highlight nicotine consumption. Then, a confirmatory analysis would be necessary to 
distinguish between smoke and smokeless tobacco use. As discussed in this section, such a method 
has not been developed yet and would require to complete part 2 of the clinical study. In these 
views, the compatibility with daily activities of Accredited Laboratories is seriously limited. Indeed, 
due to the significant prevalence of nicotine reported during the two previous studies, further 
analysis of suspicious samples with a confirmation method based on the analysis of combustion 
products would probably bring too much analytical pressure to fit with routine anti-doping analyses. 
On a further note, the recent birth of the electronic cigarette (e-cigarette) trend in Western 
countries is prone to complexity the situation, both from bioanalytical and behavioral perspectives. 
As an electronic vaping device delivering nicotine, the e-cigarette does not involve pyrolysis and 
associated combustion products but shares the same route of absorption as tobacco smoke. From a 
bioanalytical point of view, concentration profiles for part 1 and 2 obtained after e-cigarette use 
might be similar to tobacco smoke. Nevertheless, no controlled study has been reported in the 
literature yet and the metabolism of nicotine for this type of consumption remains unknown. In 
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addition, the composition of e-cigarette fluids available on the market is generally not properly 
labeled (170). Indeed, levels of nicotine, tobacco alkaloids, TSNA, aldehydes, metals, flavors, etc. vary 
considerably between and within brands (171). Likewise, the delivery and release of these 
compounds are not consistent. Eventually, nicotine levels indicated on e-cigarette fluids often 
significantly differs from the measured content. Considering the chemical heterogeneity of e-
cigarette cartridges and refill solutions might come up as an alibi provided by the athlete to disguise 
snus-like concentrations profiles. Since e-cigarette is an ever-increasing societal phenomenon, this 
excuse would also significantly challenge the assumption of ST use for performance-enhancement if 
a case was brought to court. 
 
F. Conclusion 
Completion of part 1 of the clinical study allowed building urinary concentration profiles of 
nicotine, cotinine, trans-3-hydroxycotinine and related glucuronides for 18 volunteers after smoke 
and ST consumption. Metabolism of nicotine-N’-oxide, cotinine-N-oxide, anabasine, anatabine and 
nornicotine could not be plotted due to single dose exposures resulting in trace amounts of these 
minor compounds. 
A very close fit was highlighted when comparing urinary concentration profiles obtained for 
cigarette and snus consumption. Despite a seemingly slower metabolic rate for nicotine excretion 
and a slight delay in reaching peak concentration for cotinine-glucuronide after snus consumption, 
results did not bring promising information in the perspective of distinguishing smoke from ST use. 
The additional analysis of pyrolysis products throughout part 2 of the study would most likely be very 
valuable from a theoretical point of view. However, from a practical perspective, as difficulties were 
experienced in measuring trace amounts of minor nicotine metabolites, the ability to quantify 
combustion products is very uncertain. Investing extensive efforts in the development of an 
analytical method would not be reasonable. Indeed, even if overcoming this analytical challenge 
were to be successful, the resulting methodology would certainly be of confirmatory nature, thus 
relying on a nicotine screening procedure at first. Considering the steady analytical workflow of 
Accredited Laboratories and the significant prevalence of nicotine in numerous sports disciplines, 
multiplying and developing more complicated analytical tools would be somewhat irrational. 
In light of all these elements, the ability of analytical tools to answer the phenomenon is 
questionable and another angle of approach is required to address ST use in sport. The limitations 
and challenges faced in this study put additional emphasis on the need for tackling the problem from 
the public health perspective. A preventive rather than repressive attitude should be adopted in 
order to propose proactive solutions to defuse emerging addiction and health problems associated 
with tobacco consumption.  
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 ST offers undoubtedly numerous advantages due to its odorless nature, ease of sharing, using 
and dissimulating during sports practice and at a school. Given the tobacco-free policies established 
at most schools in Western countries, ST may facilitate nicotine dosing among young (113). On a 
further note, perception of high ST use among peers and teammates might also be an initiation 
factor. With elite athletes acting as role model to lower level athletes, alleged or real improvement 
of performance in sport might be an additional driving force for use. The risks of this alternative to 
cigarette smoking are amplified by the relatively high nicotine content which is likely to initiate 
strong addiction issues. A contentious debate exists over the prediction of snus use as a potential 
gateway to smoking onset (172-174). Despite prospective studies in the United States arguing in this 
direction, a recent research found no evidence for an increased risk of smoking among ST users 
(175). Whether gateway theory applies to ST or not, the use of snus in the sports environment needs 
actions to promote cessation and discourage initiation, particularly among the youth. 
Previous studies have found intervention through peer-led educational sessions and cessation 
counseling as part of quit strategies in American high schools very efficient in helping consumers to 
stop using ST (113). However, preventing initiation through these strategies has proven to be a 
difficult goal to achieve. In views of the American experience, tackling this problematic is difficult and 
the anti-doping world would have to work hand in hand with the sports community, educational 
system and public health to refine existing strategies and develop new ones targeting populations at 
risk, among which the youth is a priority. Promoting health is a mission stated in the Code and anti-
doping bodies have to pursue educational and preventive ambitions. In order for the message to be 
well-received, helping cessation and preventing initiation is a more positive and promising answer 
than including nicotine to the Prohibited List in a repressive attitude. Nevertheless, prohibition has 
helped to reduce prevalence of other social drugs like cannabinoids. 
On a side note, the investigator has been contacted by the European Healthy Stadia Network 
(HS) organization and the World Heart Federation in the summer of 2013, rising concerns about ST 
consumption spreading throughout stadia. As health professionals, HS is keen to see a ban on the 
sale, promotion and use of all tobacco products within stadia and sports environments, to the 
benefit of fans, athletes and those living in local communities near to sports stadia. Whilst the 
argument for banning the sale and use of smoking tobacco in stadia is now well substantiated, 
banning all forms of tobacco is more difficult for stadia and governing bodies to buy into. Much of 
this can be put down to the promotional and sponsorship activities of tobacco companies who are 
now targeting sports clubs through major sponsorship and advertising deals, and hence 
building major resistance to a ban on ST. The situation of the e-cigarette flooding the market is an 
additional concern as health issues have not been fully investigated yet and as quality control of the 
production process is not well regulated either (176, 177). 
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IV.1. Conclusion & perspectives 
Anti-doping finds itself at a crossroads where the constant refinement of doping methods is 
becoming a reality requiring a change of paradigm in the lead of the fight. Research in anti-doping 
has been focusing almost exclusively on testing in order to meet the technological requirements 
linked to the continuous evolution of the List. Nevertheless, while bioanalytical tools for detecting 
the abuse of prohibited substances rapidly improved within the last decade, the problem 
simultaneously evolved towards more professionalized individual and organized doping. The 
phenomenon today is global and involves not only athletes, but also a wide variety of actors from 
physicians possessing state-of-the-art knowledge on how to dope with minimal risks to get caught to 
entourage, and a complex chain of supply for prohibited substances. The 2012 USADA vs. Lance 
Armstrong case is probably the most striking example of highly sophisticated doping where no 
adverse analytical finding was reported over the course of the most extraordinary road cycling career 
in history. Traditional doping with high doses of pharmaceutical preparations has been replaced by 
modern methods relying on micro doses and an extensive catalogue of pharmaceutical and/or 
designer drugs. This strategy has proven quite efficient in achieving the desired physiological 
response while challenging the capacity of Accredited Laboratories to detect and quantify prohibited 
agents in biological samples. 
Regardless of the individual or organized character of doping, this practice may involve 
mechanisms of criminal nature in the production and distribution of prohibited substances. 
Operating with methods borrowed from criminal organizations, doping networks have drastically 
increased in reach and density. From the ground level up to clandestine pharmaceutical plants, the 
supply of prohibited substances is a very profitable business. This attractiveness translates into 
growing numbers of producers and trafficking routes, hence the difficulty to disrupt doping when 
solely focusing on the identification of cheating athletes. A parallel may be drawn with the problem 
of illicit drugs trafficking where dismantling production and distribution networks has shown more 
impact than strictly repressing users prone to addiction issues. As athletes are end-products of a 
business, identifying and punishing these individuals has only little leverage and deterrent effect on 
doping networks. Accredited Laboratories unarguably possess state of the art technology serving 
very sophisticated research and development programs. Nevertheless, targeting the most likely 
cheaters for collecting biological samples remains a challenge. Indeed, statistics on AAFs remain 
quite stable despite a tremendous increase of anti-doping tests and bioanalytical sensitivity and 
accuracy. 
Despite testing remaining indispensable to effective anti-doping programs, exploring new 
scientific avenues to understand and highlight doping offenses so as to exert efficient preventive or 
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disruptive effects would be a welcomed addition. In this context, learning from Forensic Intelligence 
to develop Anti-Doping Intelligence might be an innovative approach to address the different aspects 
of doping, from the individual level up to the organized doping and trafficking level in a proactive 
rather than reactive way. Through logical processing of multiple sources of information gathered in a 
structured memory, Anti-Doping Intelligence might be invaluable for detecting and describing 
potential, emerging or existing doping trends. In turn, anti-doping authorities and partners of the 
fight would be provided with timely, accurate and usable information for decision-making to solve, 
reduce and/or prevent this phenomenon. Depending on the level of intelligence, focus would either 
be put on providing investigative leads on athletes and/or individuals responsible for the diffusion of 
doping, or on organized doping and the trafficking of doping to agents to identify their mechanisms 
of action and disrupt them, or eventually on the bigger picture to understand and prevent 
predisposing factors of doping. 
Forensic Intelligence being a wide area of research requiring field evaluation and validation for 
practical implementation, the studies on the use of ST in sport were a first attempt at illustrating 
phenomenon detection and follow-up functions. Starting with collating into a structured memory 
epidemiological studies on snus consumption in society, pharmacological studies on the potential of 
nicotine for performance-enhancement and information within ice hockey clubs on widespread snus 
use, a strong interest arose in investigating on the phenomenon. A prevalence study on nicotine 
consumption was first conducted during the 2009 IIHF World Championships as evidence pointed at 
this sport discipline in the first place. Analytical chemistry tools were developed and validated to 
highlight the use of nicotine by athletes. According to the results of the study, 53% of the ice hockey 
players consumed nicotine close to or/and during the games. As this prevalence was alarming, the 
premises of an intelligence-driven approach of the phenomenon were initiated to gain knowledge on 
the extent and seriousness of the problem and to provide a better description and understanding of 
current consumption patterns. Measuring the prevalence over a longer period of time and across a 
large number of sports appeared particularly relevant. Accordingly, a one-year monitoring study of 
nicotine use was conducted over 2010-2011 across all the IC samples received at LAD. Again, the 
results indicated a very significant prevalence among winter sports (up to 43.8% in snowboarding), as 
well as several ball sports (up to 55.6% in American Football) and individual disciplines (up to 37.5% 
in gymnastics). Following this study, WADA added nicotine to the 2012 Monitoring Program, which 
was a significant step towards the acquisition and further integration of global data to an organized 
memory. Through longitudinal monitoring of IC samples by seven different Accredited Laboratories 
around the world, WADA could obtain a large-scale picture of nicotine consumption distribution over 
time and space. 
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Due to the need for being able to distinguish between smoke and ST consumption and between 
recreational and doping purpose, the project was further pursued. A clinical study was designed and 
conducted in order to develop analytical and biostatistical tools for discriminating one form of 
consumption from another. During the first part of the study, the concentration profiles of nicotine 
metabolism and minor tobacco alkaloids were drawn by analyzing urine specimens after cigarette, 
and alternatively snus, consumption by healthy male volunteers. Since the route of administration 
differs, differences in the metabolic rate could be reasonably expected. The idea was to provide a 
better understanding of nicotine metabolism after smoke and ST consumption. Completion of this 
part of the study allowed building urinary concentration profiles of the most abundant nicotine 
metabolites. The high degree of similarities observed when comparing these profiles highlighted the 
need for more complex analytical tools to distinguish smoke from ST use. In particular, the study of 
combustion products, as only one consumption form involves pyrolysis, would be very valuable. 
From an anti-doping perspective, the bioanalytical methodology would have to fit with routine 
analyses while offering a satisfactory discriminative power. However, compatibility with routine 
screening procedures and the analytical workflow of Accredited Laboratories was a prime necessity 
that could be predicted as nearly impossible to fulfill. In these views, investing further human, 
temporal and economical resources into the study of pyrolysis products was not found reasonable. 
Despite being an unresolved yet, the challenge faced in distinguishing tobacco consumption 
forms is informative to WADA for decision-making on ST in sport. Indeed, these difficulties and the 
scientific data obtained through the prevalence and clinical studies stress the need to support 
educative and preventive programs on ST consumption rather than testing and repression. With 
respects to the health risks associated with tobacco and amplified by addiction issues due to 
nicotine, strategies of intervention should focus on proposing educational material, peer support and 
counseling and medical follow-up. Prevention programs should be designed to be well-received by 
athletes and the sport environment, but also by the sports community at large, from schools to 
stadia, comprising all categories and ages of sports enthusiasts. In a future perspective, this thesis 
work could be pursued in this direction, by developing, implementing and assessing the impact of 
tailor-fitted strategies for ST cessation and prevention of initiation in sport. As the e-cigarette is 
gaining huge popularity, researching on these aspects would be particularly relevant. 
Additional data would also be required to complete the logical process and to obtain a truly 
intelligence-led approach. In these regards, a behavioral study has been designed based on the 
randomized-response survey model. Every ice hockey player in a Swiss National or Regional League, 
as well as every junior ice hockey player, will be asked to fill in an extensive questionnaire addressing 
nicotine consumption. The project will be conducted in collaboration with the Institute of Sport 
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Sciences of UNIL (ISSUL) of which Prof. Fabien Ohl will be the lead supervisor of the study, the 
tobaccology department of the PMU and the Institut Universitaire de Médecine Sociale et Préventive 
(IUMSP), both affiliated to CHUV. Collating global data collected with the Monitoring Program since 
2012 and behavioral information on the perception and aim of ST consumption by the athletes 
would be very valuable. Indeed, this type of data would help determining the purpose of nicotine 
use, whether as a recreational practice or as a performance enhancer, and to understand the 
decision process behind engaging in this practice. Also, these randomized-response surveys will 
provide interesting prevalence data. When integrated to the structured memory fed by the research 
works mentioned previously, this study would add a great value to the general picture of the 
phenomenon. 
The intelligence-inspired approach followed in this thesis on ST use in sport provides anti-doping 
authorities and the sports community with comprehensive information on a little-studied 
phenomenon. The logical reasoning process was conducted to help with decision-making of 
proactive and problem-solving nature to positively impact on ST through the support of educational 
programs and peer-led assistance. From a public health perspective, prevention of initiation, risk 
reduction and help in cessation seek to provide long-term solutions. Considering the public health 
dimension of the fight against doping, this attitude would be a novel and interesting approach to 
detect and tackle emerging or existing consumption dangers.  
Anti-Doping Intelligence possesses an unarguable potential for the gathering of information on 
any type of phenomenon in order to understand its underlying mechanisms and to identify key 
points for intervention. Following the research initiated in this thesis, further evaluating and putting 
to test all the different aspects of the concept in the real world would be essential to come up with 
an operational system. If indeed such a system could be placed in a central location (WADA perhaps) 
and supplied and supported by anti-doping professionals, there is no doubt that this would be a 
major step forward. 
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